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ABSTRACT PAGE
Effective diagnosis and treatment of breast cancer rely on a precise and detailed 
understanding of the cellular-molecular alterations that give rise to an oncogenic 
phenotype. With the advent of new imaging technologies investigators have begun to 
follow mammary tumor development in vivo and noninvasively with high resolution and 
sensitivity. Continued progress requires combining molecular biology and imaging with the 
goal of imaging the metabolism of specific tumor-related molecules. As a result, we have 
developed a novel small animal gamma camera that is capable of detecting low levels 
(0.52 MBq, 14 uCi) of radioiodine (125AI). The dynamic uptake of 125AI through the sodium 
iodide symporter (NIS) was used to detect the progression of spontaneous mammary 
tumors in th^ mouse mammary tumor virus (MMTV) model as well as  the transgenic 
animal model expressing the polyoma middle T oncoprotein (PyVT). Based on whole 
mount immunohistochemistry, NIS protein expression correlates with the gamma camera 
images of 125AI, which is also a promising radiotracer for detecting small, non-palpable 
tumors (3 mm). Additionally, gamma imaging was capable of identifying PyVT mice from 
their wild type littermates based upon their ability to accumulate 125AI in nulliparous 
mammary glands as  early as  5 weeks of age. MMTV tumors are classified into three 
groups based on their unique 125AI distribution that is correlated with tumor size, but not 
propagation rate. Differences in 125AI uptake gain (or loss) are dynamic especially during 
early dose administration. Finally, mammary glands show differences in uptake pattern 
when a tumor is present.
Taken together, these results suggest that radioiodide imaging is a promising in vivo 
method for monitoring the changes associated with tumor development such as changes of 
tumor size, pattern, and aspects of gene-specific metabolism over both short and long 
durations. Our results also indicate that the classifiable heterogeneity present in dynamic 
gamma camera images may correlate with specific patterns or signatures of gene 
expression that, in turn, indicate tumor subtype and progression. These data may allow 
investigators to develop an effective and sensitive system of in vivo imaging of molecules 
and metabolism that reflect the molecular signature of a tumor in real time. Our system 
may provide a m eans for early detection, ideally even a precancerous state before 
malignancy develops, and a method to asse ss  the overall state of a tumor with the goal of 
predicting the best therapeutic regime and following the efficacy of the therapy in real time 
by examining specific molecular targets.
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CHAPTER 1
INTRODUCTION
Overview
Breast cancer is a major and important disease with heavy clinical and personal 
burden. This year alone the predicted number of new breast cancer cases in the United 
States will reach a record high of approximately 200,000 individuals, and despite the 
decline in overall mortality from breast cancer, approximately 20% of those diagnosed 
will succumb to the disease (Jemal et ah, 2009). In view of this high statistic, there are 
pressing needs that must be addressed in breast cancer research including: the need for 
appropriate models to study, the need for continued molecular understanding of the 
disease, and the need for in vivo imaging to follow cellular and metabolic processes at the 
molecular level.
While there are many models currently employed, mice carrying the mouse 
mammary tumor virus (MMTV) have served as one of the oldest and most established 
models for human breast cancer (Cardiff and Kenney, 2007). MMTV is a transforming 
retrovirus that causes mammary tumorigenesis in mice which can be inherited as an 
endogenous retrovirus through the germline or acquired exogenously via transmission 
through the milk (Ross, 2008). There has been extensive analysis of the molecular 
genetics of the virus and the mechanisms underlying tumorigenesis for the last seventy 
years. However, despite its importance as a model, there has been relatively little done to 
address the physiological and metabolic progression of these mammary tumors,
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particularly in an in vivo context (Gabrielson et al., 2008). The advent of in vivo imaging 
allows us to address these important issues of longitudinal monitoring of molecular 
processes for this key and often utilized model.
Here we use in vivo gamma imaging with radioiodine combined with molecular 
biology assays targeting the sodium iodide symporter (NIS) to address specific questions: 
1.) Do MMTV tumors display a unique radioiodine metabolic pattern? 2.) Does the 
presence of a mammary tumor influence other aspects of physiology/metabolism? Many 
have shown that NIS, the protein that facilitates radioiodine transport into cells, is 
upregulated in the majority of human and transgenic mouse mammary cancers 
(Knostman et ah, 2004; Renier et al., 2009; Tazebay et al., 2000; Wapnir et al., 2003). 
Based upon these data, we hypothesize that there will be unique radioiodine 
accumulation patterns that are associated with NIS expression and that the metabolism of 
radioiodine in other tissues will be affected due to the presence of a tumor.
Epidemiology and Molecular Biology of Breast Cancer
Risk factors that have been associated with breast cancer development include 
early age at menarche, low birth rate, infertility, and advanced age at menopause (all 
reviewed in Cetin et al. (2008)). Additionally, greater breast density (Boyd et al., 2009), 
advanced age (Crivellari et al., 2007), obesity and increased circulating endogenous 
estrogens (reviewed in Cleary and Grossmann (2009)), and environmental factors, such 
as smoking at an early age (Ha et al., 2007) have also been linked with increased breast 
cancer risk.
Two genes, BRCA1 and BRCA2, are associated with “high risk” breast cancer
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susceptibility, but mutations in these genes are rare and account for only 10% of breast 
cancer cases (Metcalfe, 2009). Current evidence suggests that along with mutated 
versions of the BRCA1 and BRCA2 genes, concomitant mutations in “low risk” breast 
cancer susceptibility genes, like checkpoint kinase (CHEK2), have been shown to double 
an individual’s risk of breast cancer (Nevanlinna and Bartek, 2006).
The amplification of the c-Myc transcription factor has been linked to breast 
cancer because of its ability to regulate transcription of up to 15% of all genes 
(Bouchalova et al., 2009). Likewise, other molecular targets that are frequently associated 
with increased breast cancer risk include: mutation and overexpression of ras (Pylayeva 
et al., 2009) and src (Jin et al., 2008) signaling pathways, the inactivation of p53 
(Golubovskaya et al., 2009) and overexpression of cyclin D1 (Butt et al., 2008), both of 
which control the cell cycle, and the loss of the adhesion molecule E-cadherin (Baranwal 
and Alahari, 2009).
Estrogen receptor-a (ERa), progesterone receptor (PR) and human epidermal 
growth factor receptor-2 (HER2/ErbB2) are the only biomarkers that are currently used 
for testing in breast biopsies in order to determine therapy options (Geyer et al., 2009). 
ERa and PR are both steroid receptors that when bound to their respective hormones 
become activated and bind as dimers to steroid responsive elements on the DNA to 
regulate gene transcription (Wei et al., 2009). ERa and PR breast cancer expression have 
been reported at higher levels in male breast cancer (90%) compared to female (75%) 
(Robinson et al., 2008). E1ER2 is an epidermal growth factor receptor tyrosine kinase that 
is expressed in approximately 30% of breast cancers (Pritchard et al., 2008). In clinical 
applications the receptor status of these three biomarkers is used as a tool to predict
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treatment methods (tamoxifen for ERa and PR or trastuzumab for HER2) and long-term 
prognosis. In general, ERa and PR positive and HER2 negative breast cancers are more 
easily treated because they will respond to hormone therapy. HER2 positive cancers are 
harder to treat because of drug resistance, and ERa, PR, and HER2 negative tumors are 
some of the most aggressive with the poorest overall prognosis (Geyer et al., 2009; 
Renier et al., 2009).
Amphiregulin (AREG) is a member of the epidermal growth factor family that 
activates epidermal growth factor receptor (EGFR) related receptors such as HER2. In 
the normal mammary gland AREG has been shown to be critical for the outgrowth of 
mammary ducts into the fat pad (Lamarca and Rosen, 2007; Lawson, 2009). In breast 
cancer, ER-positive status has an influence on the expression of AREG. It has been 
reported that AREG mRNA is expressed in as much as 58% of breast carcinomas 
(Normanno et al., 1995). AREG has also been linked to breast cancer progression. 
Increased expression of AREG mRNA and protein were found in the tumors of four 
transgenic mice strains, such as HER2, which suggested that AREG had a role in tumor 
progression (Kenney et al., 1996).
Hypoxia-Inducible Factor-1 alpha (HIF-la) is a transcription factor responsible
for the cellular response to hypoxia. There are two subunits comprising the transcription
factor, H IF-la and HIF-lp (Kronblad et al., 2006). HIF-lp is constitutively expressed,
but H IF-la is degraded under normoxic conditions and during hypoxia it dimerizes with
HIF-lp in order to bind to hypoxic responsive elements on the DNA to regulate gene
transcription. HIF-1 complex has been shown to regulate genes involved with
angiogenesis, glycolysis, cell survival and cell invasion (Semenza, 2003). In the
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involuting mammary gland, mRNA hierarchal clustering analysis has been used to cluster 
genes into finite groups based on the time they are activated during the regression of the 
mammary gland post-weaning. This analysis identified the most overexpressed genes 
during involution were those with HIF-1 promoter binding sites, which suggests 
pathways involved with metastasis are activated during this time (Stein et al., 2009). HIF- 
l a  can also be overexpressed in breast cancer. Kronblad et al. (2006) have demonstrated 
that poor prognosis and ultimately death in breast cancer is correlated with H IF-la 
overexpression. Recently, H IF-la overexpression in a transgenic model was not 
sufficient to induce mammary tumor growth, but it plays a role in tumor metastasis (Liao 
et al., 2007). Viola et al. (2008) have reported detecting the increase in H IF-la 
expression in transplanted breast carcinomas.
Breast Cancer Models
Transgenic Models o f Breast Cancer
An objective in the design of transgenic genetically engineered mouse (GEM)
models has been to better understand the molecular mechanisms driving mammary
tumorigenesis and progression especially as it may relate to human disease. The
histopathology of most GEM models of breast cancer do not appear to resemble
spontaneous tumors induced by the mouse mammary tumor virus or chemical
carcinogens (Cardiff et al., 2000a), but GEM tumors do closely resemble human breast
cancers especially in premalignant ductal carcinoma in situ (Cardiff and Wellings, 1999;
Maglione et al., 2001). Although GEM and human tumors can have morphological
similarity, the tumor biology of these species is different. These differences are evident
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with regard to tumor composition, cell type, estrogen receptor status, and site of 
metastasis (reviewed in Marcotte and Muller (2008)). Nevertheless, transgenic models 
that imitate components of human breast cancer have and will continue to be useful tools 
for studying mammary tumorigenesis.
The development of transgenic mammary tumor models has employed promoter 
regions of the mouse mammary tumor virus (MMTV) long terminal repeat, Beta- 
lactoglobulin (BLG), C3 promoter, or the whey acidic protein (WAP) fused to oncogenes 
of interest to target mammary epithelia for expression (reviewed in Cardiff et al. 
(2000b)). These promoters are hormone responsive and generally require multiple 
pregnancy/lactation cycles in order to get significant transgene expression in the 
mammary glands. Transgenic models commonly employed for studying how disregulated 
pathways initiate and promote mammary tumorigenesis include: MMTV-TGFa, 
transforming growth factor a  (growth factors), MMTV-ErbB2/neu, epidermal growth 
factor receptor (receptors), WAP-Int3, Notch (differentiation), MMTV-Myc (cell-cycle), 
and MMTV-PyVT, polyomavirus middle T antigen (signal transduction) (reviewed in 
Cardiff et al. (2000b) and Marcotte and Muller (2008)).
Currently, the MMTV-polyoma middle T antigen (PyVT) mouse is extensively
used in breast cancer research because of the model’s rapid tumor development and its
metastatic ability. In the PyVT MT#634 mouse line, by three weeks of age multiple
premalignant adenocarcinomas were detected; by five weeks of age highly fibrotic
tumors developed in the entire mammary fat pad which inhibited lactation; by three
months of age 94% of tumor-bearing females developed multiple metastatic
adenocarcinoma foci of mammary origin in the lungs (Guy et al., 1992). At the molecular
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level, PyVT binds and activates signal transduction pathways involved with cell 
proliferation, migration, and apoptosis. Specifically, PyVT activates both the c-Src family 
of tyrosine kinases (Guy et al., 1994) and the phosphatidylinositol 3-kinase (PI3K) 
(reviewed in Vivanco and Sawyers (2002)) signaling pathways, which have been shown 
to be critical for tumor initiation, but inefficient to drive the malignant phenotype in 
PyVT animals (Maglione et al., 2001). Much has been done to describe the discrete 
stages of tumor progression in the PyVT model beginning with hyperplasias and ending 
with carcinomas. Maglione et al. (2001) identified that the pre-dominant premalignancy 
lesions found in PyVT mice were ductal carcinoma in situ (DCIS) which were 
tumorigenic in transplant studies and gave rise to metastatic lesions. In addition, Lin et al. 
(2003) have reported that with PyVT tumor progression, there is a steady loss in estrogen 
and progesterone receptors and an overexpression of the ErbB2/neu receptor. 
MMTVModel
Beginning in 1936, Dr. John Bittner demonstrated that viremic dams from mouse 
strains with high mammary tumor incidence secreted a “milk factor” causally associated 
with tumorigenesis both in progeny and in fostered pups from low incidence strains. 
These data along with later work suggested that the etiology of the maternal tumorigenic 
contribution stemmed from an infectious virus called the mouse mammary tumor virus 
(MMTV) (reviewed in Cardiff and Kenney (2007)). MMTV is a murine B-type retrovirus 
incorporating its DNA as a provirus into the genome of infected host cells. The infectious 
insertion of MMTV viral DNA occurs in two forms: exogenous transmission from 
mother to pup or in rare events endogenous transmission through the germline (Callahan 
and Smith, 2000).
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Horizontal transmission of exogenous MMTV begins following pup ingestion of 
infected milk from viremic dams exposing MMTVs to B cell lymphocytes traveling 
through Peyer’s patches in the gut. Subsequent incorporation of the exogenous pro virus 
into B lymphocyte genomes trigger the expression of the MMTV sag gene encoding a 
superantigen (Acha-Orbea and MacDonald, 1995) in the long terminal repeat (LTR) 
sequence, which stimulates the recruitment and proliferation of MMTV infected T cell 
lymphocytes with Vp receptors (Beutner et al., 1994). Infected lymphocytes expose 
MMTVs to neonatal mammary gland epithelia leading to viral quiescence. The exact 
mechanism for virion binding to the host is unknown, but cell-to-cell interaction 
(Callahan and Smith, 2000) or interaction with acidic receptors such as mouse transferrin 
receptor 1 (Ross et al., 2002) are the prime candidates.
Recently, studies have suggested that because MMTV tumors are clonal the initial 
viral infection targets mammary precursor/stem cells which can differentiate into all 
mammary epithelia cell types (Callahan and Smith, 2008; Medina, 2005). Dormancy is 
interrupted during puberty when under hormone regulation mammary epithelia begin to 
proliferate forming the ductal structures of the breast. Once again the proviral LTR 
encodes mammary specific enhancers (Mink et al., 1992; Mok et al., 1992) or hormone 
response elements interacting with glucocorticoids, androgens and progesterone/prolactin 
during pregnancy (reviewed in Gunzburg and Salmons (1992)) to stimulate MMTV 
virion production and infection of new mammary epithelia. Estrogen does not 
specifically affect expression of viral DNA (Bocchinfuso et al., 1999; Otten et al., 1988), 
but there is a positive correlation with estrogen activity and MMTV virus levels (Bradlow 
et al., 1985).
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As the MMTVs continue to infect mammary epithelia, tumorigenesis occurs via 
insertional mutagenesis constitutively activating adjacent proto-oncogenes (Theodorou et 
al., 2007). During oncogenesis MMTVs activate a wide range of ectopic genes not 
normally expressed in the mammary gland such as Wntl/Intl (Nusse et al., 1984), 
Fgf3/Int2 (Mester et al., 1987; Shackleford et al., 1993), and Notch4/Int3 (Politi et al., 
2004; Uyttendaele et al., 1996), which have been shown to act in combination with one 
another to promote tumorigenesis (Mester et al., 1987). Furthermore, MMTVs activate 
genes involved with Wnt, MAPK, Notch, Hedgehog, FGF, and EGF signaling pathways 
(Callahan and Smith, 2008; Theodorou et al., 2007).
Many inbred mice strains and some feral mice have vertically transmitted or the 
endogenous MMTV provirus in their genomes acting under the constraints of Mendelian 
gene assortment (Michalides et al., 1981; Varmus et al., 1972). Compared with the 
exogenous form, endogenous MMTV is less virulent and rarely causes tumorigenesis 
(Ponta et al., 1985). Endogenous MMTV has also been shown to provide critical 
resistance to exogenous MMTV infection when the exogenous and endogenous viruses 
stimulate the same type of VP T cells (Beutner et al., 1994; Golovkina et al., 1997). 
Additionally, endogenous and exogenous MMTVs are secreted during lactation and have 
been shown to undergo recombination to mitigate virulence, though without the 
exogenous form the endogenous provirus is inert (Golovkina et al., 1994; Golovkina et 
al., 1997; Hook etal.,2000).
The MMTV model is currently used for breast cancer research because of the 
homology between murine and human development and maturation of mammary glands, 
as well as, the model’s apparent spontaneous ability for tumor development (Cardiff and
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Kerrney, 2007; Cardiff and Wellings, 1999). Like the majority of human breast cancers, 
spontaneous MMTV tumors are estrogen receptor positive compared to transgenic breast 
cancer mouse models whose tumors are overwhelmingly estrogen receptor negative 
(Kordon, 2008). MMTV study also offers insight into viral tumorigenesis that may be 
linked to some human breast cancers (Lawson et al., 2001), though the data remains 
equivocal (Lawson, 2009). MMTV-infected mouse models have also been used to 
describe the effect that endocrinology, viruses, signaling and oncogenes have on 
neoplastic progression (reviewed in Cardiff and Kenney (2007)).
In Vivo Imaging of Breast Cancer
Early detection, diagnosis, and treatment of breast cancer provide the best 
survival strategy against the disease (Prasad and Houserkova, 2007). Imaging modalities 
such as mammography and magnetic resonance imaging (MRI) are most widely 
employed for breast cancer screening and early detection in the clinical setting. While 
these technologies provide critical anatomical information about lesion location, they 
lack the capacity to convey any functional information (Bartella et al., 2007). 
Implementing functional imaging modalities, such as positron emission tomography 
(PET) and single photon emission computed tomography (SPECT), would complement 
current screening technologies because of the added information about the biology of the 
tumor (Culver et al., 2008).
Mammography
Mammography remains the most widely employed method for screening and 
diagnosing breast cancer throughout the world (Skaane, 2009). This detection modality
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uses a controlled amount of ionizing X-rays to record breast density variation as the 
radiation waves pass through the tissues (Matveeva et al., 2009). The image produced 
from this screen can identify dense masses within the breast tissue that would appear 
abnormal and warrant further testing. Currently, many clinics are shifting from the 
standard screen-film mammography to full-field digital mammography which has been 
shown to be just as effective at breast screening (Skaane, 2009; Vinnicombe et al., 2009). 
However, since the effectiveness of mammography relies on lower breast density for 
abnormal mass detection, more dense breasts are difficult to accurately screen. This 
diagnostic problem can lead to false positive or inappropriate negative results, although it 
has recently been shown that breasts with a density of 75% have a higher likelihood of 
cancer development (Boyd et al., 2009). While mammography is reliable at detecting 
anatomical anomalies within the breast, it does not convey any type of functional 
information about putative tumors.
Magnetic Resonance Imaging
MRI is an imaging modality with excellent spatial resolution for anatomical 
imaging and is used in adjunct to mammography. MRI now possesses potential 
functional imaging capability, but lacks any molecular or metabolic information (Prasad 
and Houserkova, 2007). With the aid of radiowaves, a MRI scan measures the protons in 
water and can distinguish between tissue types based on differences in water 
concentrations (Lyons, 2005). In addition, dense areas with higher blood supply are more 
easily imaged with MRI. In many cases contrast agents containing gadolinium are used to 
enhance image quality (Mortellaro et al., 2009).
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Although in the clinical setting MRI remains primarily used for anatomical scans, 
new advances are coming to the forefront. Specifically in breast cancer imaging studies, 
MRI not only provides anatomical information, but also has showed promise in 
functional analysis. MRI has been shown to detect choline in breast cancers that is 
generally undetectable in normal breast tissue (Tozaki, 2008). Differences between 
imaging kinetics of choline detection in estrogen receptor (ER) positive and negative 
breast cancers have been evaluated (Chen et al., 2008). Additionally, MRI was shown to 
have greater ability at detecting lesions in older patients with HER2 receptor negative 
breast cancers (Moon et al., 2009). MRI has also been employed for axillary lymph node 
monitoring for possible metastasis since lymph nodes of receptor negative breast cancers 
have been shown to be larger than receptor positive breast cancers (Mortellaro et al., 
2009). However, despite these advances, MRI still has remained an anatomical tool for 
detecting breast lesions without any functional information about the tumor metabolism. 
Positron Emission Tomography
Positron emission tomography (PET) has become the primary modality for
ic n
functional and molecular imaging using positron-emitting radioisotopes, such as O, N, 
HC, and 18F (Benard and Turcotte, 2005). The most utilized radiotracer for PET is 2-
1 o 1 o
Deoxy-2-[ F] fluoro-D-glucose ( F-FDG), which can detect elevated glucose
1 Rmetabolism in breast cancer (Almubarak et al., 2009). Briefly, the mechanism behind F-
1RFDG breast cancer imaging involves the glycolytic pathway. Within cancer cells F-
i  o  * 1 R
FDG is phosphorylated by hexokinase into F-FDG -6-phospate, and from this point F- 
FDG -6-phosphate can neither be released from cells nor further broken down for 
metabolism. In practice, breast cancer cells have a higher glycolytic rate than
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surrounding normal tissue which PET can detect due to greater positron emission 
(Lavayssiere et al., 2009).
In contrast with imaging modalities, such as mammography or MRI, PET 
provides in vivo functional information about the differences between normal and tumor 
glucose metabolism. This functional application for PET has led to studies correlating 
18F-FDG uptake with other tumor parameters, such as HER2 (Dijkers et al., 2009), ER 
and PR receptor status (Basu et al., 2008; Mavi et al., 2007), tumor size (Buck et al., 
2002), and tumor histology (Mavi et al., 2006). Small animal PET imaging with 18F-FDG 
has also been demonstrated as a useful tool for longitudinal monitoring of mammary 
tumor development in transplant studies (Abbey et al., 2006). In addition, small animal 
PET imaging has become a useful tool to target angiogenesis (Chen et al., 2004), and 
examine both tumor treatment response (Kesner et al., 2007) and therapy options (Aliaga 
et al., 2007; Hsueh et al., 2006; Parry et al., 2009).
However, despite the increasing number of radiotracers that have been evaluated
1 Rfor PET imaging, such as targeting estrogen ( F-fluoroestradiol (Dehdashti et al., 2009;
1 8Peterson et al., 2008)) or treatment options with 4-[ FJfluoropaclitaxel (Hsueh et al., 
2006; Kurdziel et al., 2007), in all clinical applications 18F-FDG is used. Therefore, there 
is a need for other PET radiotracers for general imaging applications (Ballinger, 2008). 
PET tracers also have very short half-lives and require a cyclotron to produce the 
complicated radiochemistry (Rahmim and Zaidi, 2008). False negative results can occur
1 o
due to the poor resolution of PET to detect both low F-FDG accumulation in lobular 
carcinomas and small tumors (0.4-1.5 cm) (Benard and Turcotte, 2005; Zytoon et al., 
2008). False positive results can occur with PET in benign inflammations and
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fibroadenomas of the breast. Multiple studies have demonstrated that lesions with higher 
concentrations of inflammatory cells, such as neutrophils and activated macrophages, also
1 0
have elevated F-FDG uptake, which can be misdiagnosed as malignancy in patients 
with proven or suspected cancer (Fenchel et al., 2002; Zhung and Alavi, 2002). While
1 o
PET imaging with F-FDG provides greater in vivo functional applications, limitations 
on tracer availability, specificity, and resolution require have opened the door to other 
imaging techniques with gamma emitters.
Scintimammography /  Single Photon Emission Computed Tomography (SPECT)
As with PET, scintimammography (including planar and SPECT) relies on 
gamma ray emitting tracers, such as " mTc-sestamibi, 123I, 125I, and 13 \  tagged to ligands 
for targeted molecular analysis. Compared with PET imaging, SPECT has lower 
sensitivity, but with the aid of pinhole collimators can achieve submillimeter spatial 
resolution (Mariani et al., 2008; Rowland and Cherry, 2008). Additionally, there are 
many commercially available iodinated ligands for targeted in vivo molecular imaging 
with SPECT (Weisenberger et al., 2003). The longer half-lives of isotopes used in 
SPECT are beneficial for longitudinal studies and for detecting slow biological processes 
(Rahmim and Zaidi, 2008).
In the clinical setting nuclear breast imaging via gamma cameras are employed 
with " mTc-sestamibi because of increased sestamibi uptake in breast tumors compared 
with normal breast tissue (Gommans et al., 2007). Also there are conflicting reports on 
the usefulness of sestamibi washout as a predictor of poor chemotherapy response 
(Cwikla et al., 1999; Fuster et al., 2002; Tiling et al., 2004; Travaini et al., 2007). 
Currently, clinical gamma imaging is primarily used with equivocal mammograms due to
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breast density (Zhou et al., 2008), and have been shown to have higher sensitivity at 
detecting occult breast lesions (Brem et al., 2008; Brem et al., 2007). The use of double 
gamma cameras has been shown to more accurately quantify lesion size and depth away 
from the collimator (Hruska and O'Connor, 2008).
SPECT imaging has been adapted for other targeted imaging of apoptosis markers 
(Kim et al., 2007a; Mandl et al., 2004), VEGF (vascular endothelial growth 
factor)(Collingridge et al., 2002), endoglin (Fonsatti et al., 2000), EGFR (Fernandes et 
al., 2007), anti-HER2 antibody (Orlova et al., 2007), and ER (Nayak et al., 2008). For 
small animal imaging studies there are now commercially available imaging devices 
dedicated to SPECT imaging, such as nanoSPECT (BioScan Inc.) (Garrood et al., 2009), 
X-SPECT (Gamma Medica Inc.) (Kim et al., 2007a) and U-SPECT-II (Molecular 
Imaging Laboratories) (van der Have et al., 2009). Recently, it has been shown that small 
animal SPECT imaging can be accomplished without the use of collimators and with a 
resolution of 7 mm (Mitchell and Cherry, 2009).
The transmembrane protein, sodium iodide symporter (NIS), has become a 
significant molecular target for SPECT imaging approaches due to its expression in 
organs such as the thyroid, stomach, lactating mammary glands, and in many human 
breast cancers (Carrasco, 1993; Dohan et al., 2006; Wapnir et al., 2004; Zuckier et al., 
2001). NIS facilitates the transport of iodine into the cells in which it is expressed. 
Gamma ray emitting isotopes, such as radioiodine, can directly target the molecular 
expression and function of NIS (Zuckier et al., 2004). In addition to the utility of NIS for 
in vivo imaging, it has also been used as a target for gene therapy (Dadachova and 
Carrasco, 2004; Fan et al., 2004).
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The Sodium Iodide Symporter and Breast Cancer
NIS is a transmembrane protein responsible for the cellular transport of iodine 
from the blood. NIS is primarily expressed in the thyroid for organification of thyroid 
hormones, but is also expressed in the gastric mucosa, lactating mammary glands and 
certain breast cancers (Spitzweg and Morris, 2002). Tazebay et al. (2000) were the first to 
establish in rats that lactating mammary glands had the specificity to accumulate 125I 
compared to non-lactating rats. Physiologically, iodine secretion into the milk substrate 
has been shown to be critical for neonatal thyroid hormone development and storage, as 
well as, preventing impaired neurological development (Azizi and Smyth, 2009).
NIS Expression in Mouse Mammary Tumors
NIS expression and in vivo function, via scintigraphic imaging with " mTc- 
pertechnetate, was first described in the Her-2/neu and v-Ha-ras transgenic mouse models 
(Tazebay et al., 2000). Research has shown that the polyomavirus middle T antigen 
(PyVT) mouse model has increased radioiodine uptake in mammary tumors when NIS 
mRNA expression was induced with all-trans retinoic acid (Kogai et al., 2004). NIS 
protein localization in breast cancer tissues has significant differences from the normal 
expression patterns in the basolateral surface of lactating alveolar cells. Knostman et al. 
(2004) identified endogenous NIS protein expression in the PyVT, MMTV-Cox-2, Ubi- 
hCG(3, and MMTV-neu transgenic mouse models. NIS in these transgenic samples was 
sometimes expressed on the plasma membrane and sometimes compartmentalized 
intracellularly. In vivo function of NIS was analyzed in PyVT mice using scintigraphy to
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131 188monitor tumor growth inhibition with radioiodine ( I) and perrhenate ( ReOT) 
treatment (Dadachova et al., 2005).
NIS Expression in Human Breast Cancer
In human breast cancer NIS is expressed in many mammary carcinomas. Tazebay 
et al. (2000) found that 87% of invasive carcinomas, 83% of ductal carcinomas in situ, 
and 23% of noncancerous samples in the vicinity of the tumors expressed NIS protein. 
Next, a massive immunohistochemical study of 371 human breast cancer samples 
revealed that NIS was expressed in IHC 88% of ductal carcinomas, 76% of invasive 
carcinomas, and 87% of normal breast samples were negative (Wapnir et al., 2003). The 
high prevalence of NIS expression in mammary carcinomas compared with normal tissue 
overwhelming suggests that NIS could be used as a biomarker in this type of cancer. The 
current accepted biomarker for breast cancer, HER2, has very low (33%) positivity with 
this cancer type, which suggests that NIS positivity in tandem with isotope accumulation 
would be a sufficient biomarker in mammary carcinomas (Dohan et al., 2003). Recently, 
NIS expression has been identified in 65% of breast cancer samples that were negative 
for the three most common breast cancer markers, estrogen receptor (ER), progesterone 
receptor (PR), and HER2, further implicating the applicability of NIS as an efficient 
biomarker (Renier et al., 2009). Functional NIS has been evaluated using " mTc- 
pertechnetate scintigraphy in human primary breast tumors and isotope accumulation was 
positively correlated with NIS mRNA levels (Moon et al., 2001; Upadhyay et al., 2003).
In the ER+ human breast cancer cell line, MCF-7, all-trans retinoic acid has been 
shown to induce NIS mRNA expression and radioiodine uptake (Kogai et al., 2004; 
Kogai et al., 2008). Others have indicated that enhanced induction of NIS expression is
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accomplished with all-trans retinoic acid in addition to dextamethasone (Unterholzner et 
al., 2006; Willhauck et al., 2008). NIS activity and radioiodine accumulation have been 
stimulated by prostaglandins (PGE2), human chorionic gonadatropin (hCG), and 
phosphatidylinositol 3-kinase (PI3K) in MCF-7 cells. In contrast, cAMP, involved with 
NIS activity in the thyroid, stimulated NIS promoter activity but was not sufficient to 
induce radioiodine accumulation in MCF-7 cells (Knostman et al., 2004). Recently, 
studies have further found that PI3K in MCF-7 cells directly facilitates all-trans retinoic 
acid induction of NIS expression (Kogai et al., 2008; Ohashi et al., 2009). In the human 
ER- breast cancer cell line, MDA-MB-231, agents that have induced NIS expression in 
MCF-7 cells, such as all-trans retinoic acid and PI3K, do not effect NIS levels in this cell 
line (Knostman et al., 2007b; Kogai et al., 2004).
Current research suggests that there is a troubling disparity between the number of 
breast cancers that are positive for NIS protein versus their ability to accumulate any 
detectable radioiodine. Although up to 80% of human breast cancers have been shown to 
be positive for NIS (Wapnir et al., 2003), as few as 25% of these positive tumors have the 
ability functionally accumulate radioiodine in a manner useful for imaging or ablation 
with 131I (Beyer et al., 2008). Many have observed that NIS localization in breast cancers 
is intracellular, which suggests impairment of cell surface trafficking. In the MCF-7 cell 
line, upregulation of NIS expression via the PI3K pathway has been shown to produce 
underglycosylated NIS which cannot be trafficked to the cell surface. In addition, PI3K 
activation of NIS has inhibited endogenous NIS expression and function at the cell 
membrane (Knostman et al., 2007b). Peyrottes et al. (2009) have designed and tested new
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antibodies against NIS and have implied that the majority of intracellular NIS localization 
can be attributed to non-specific staining.
Goals of Project and Hypothesis
The goals of this work were to validate the efficacy of a novel second generation 
gamma camera (Bradley et al., 2006) as a high-performance imaging modality 
specifically for breast cancer research, and to address the need for in vivo imaging 
techniques which monitor the physiological and metabolic progression of mammary 
tumors. Specifically we wished to address important questions on MMTV biology: 1.) Do 
MMTV tumors display a unique radioiodine metabolic pattern? 2.) Does the presence of 
a mammary tumor influence other aspects of physiology/metabolism? The gamma
I
camera was used to monitor the dynamic uptake of I through the functional activity of 
NIS in spontaneous mammary tumors induced by the expression of the mouse mammary 
tumor virus (C3H/HeN MMTV+) as well as transgenic mammary tumors induced by the 
expression of the polyomavirus middle T antigen (FVB/N-Tg (MMTV-PyVT)634Mul). 
Many studies have shown that in both human and transgenic mammary tumors NIS is 
upregulated (Knostman et al., 2004; Renier et al., 2009; Tazebay et al., 2000; Wapnir et 
al., 2003), and based upon these findings we hypothesize that in the MMTV model we 
can detect the unique 125I accumulation patterns that provide information about where 
NIS protein is expressed. Additionally, based on other studies we hypothesize that the
i
metabolism of I in other tissues will be affected when a mammary tumor is present.
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CHAPTER 2
MATERIALS AND METHODS
Animal Models
Mice (24-33 g body weight) six months and older were derived from the 
C3H/HeN MMTV+ strain (National Cancer Institute, Frederick, Maryland), and 
characterized by tumor development due to exogenous transmission of the MMTV virus. 
The C3H/HeN breeding founders were generously donated by Dr. Tatyana Golvkina. 
This study also integrated the smaller (22-29 g body weight) C57BL/J6 strain (Jackson 
Laboratory, Bar Harbor, ME) mice for comparative studies of radioiodide uptake in 
normal nulliparous, lactating, and multiparous mammary glands.
Heterozygous male FVB/N mice (National Cancer Institute, Frederick, Maryland) 
expressing the polyomavirus middle T antigen (FVB/N-Tg (MMTV-PyVT) 634Mul) under 
the control of the mammary-specific mouse mammary tumor virus long terminal repeat 
promoter were bred with wild type females. Both wild type and heterozygous transgenic 
females (27-42 g body weight) five weeks and older were used for in vivo studies. For 
transgenic screening studies two groups of weaned pups, the first at 5 weeks old and the 
second at 7 weeks old, were selected at random from litters. Mice were screened for 10 
minutes using the compact gamma camera fifty minutes after the radioiodine was 
administered. Mice were returned to their cage following imaging and later sorted into 
groups based on how they accumulated radioiodine.
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All murine studies were performed in accordance with protocols approved by the 
College of William & Mary IACUC animal committee. Anesthesia of animals was 
performed using sodium pentobarbital (50-90 mg kg'1 body mass) injected into the 
peritoneal cavity. Spontaneous and transgenic tumor palpability in mature mice was 
evaluated bi-weekly. Following anesthesia an animal selected for imaging was
10 Ssubcutaneously injected in the femoral bicep with 0.52 MBq (14 pCi) Na I 
(PerkinElmer, Waltham, MA) in 0.10 ml 0.9% saline as described in (Bradley et al., 
2006). The animal was oriented supine on the detector during the imaging period and 
monitored throughout for rhythmic breathing.
In Vivo Gamma Imaging and Data Acquisition
The compact second generation gamma camera developed for “mouse-sized” 
biological planar imaging by (Bradley et al., 2006) was used for this study (Fig. 2.1). The 
compact detector incorporating a pair of 2-in square Hamamatsu H8500 positron 
sensitive photomultiplier tubes (PSPMTs) was installed on a gantry. The PSPMTs were 
optically coupled to a pixellated Nal(Tl) crystal array, each element measuring 1 x 1 x 5  
mm3 separated by 0.2 mm reflective walls. A 5 mm thick CuBe collimator designed for
1 c #
imaging 30 keV photons emitted from I was employed with 0.55-mm square openings 
separated by 0.11 septa. This collimation provides a spatial resolution (FWHM) of 2.5 
mm on contact with the collimator with an effective area of about 46 x 96 mm . The 
detector and related data acquisition instruments were interfaced to a computer. Each 
photon detected by the gamma camera was referred to as an “event”. A program
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developed with data acquisition software Kmax (Sparrow Inc., Sierra Vista, Arizona) 
recorded the time, energy and computationally determined coordinates of every event 
sorted into event files.
Image Analysis
An analysis program developed with data processing and visualization language 
IDL (Research Systems Inc, Boulder, Colorado) was used to group event files into five- 
minute intervals recorded as two-dimensional matrices (referred to as “timecuts”). Each 
imaging session produced timecuts representing twelve five-minute digitized gamma 
images. The digital coordinates of each pixel (1.2 x 1.2 mm ) correspond with the planar 
position where the counts of isotope decay in the mouse as visualized by the detector. 
The total counts that were recorded at each pixel represent the radioactivity detected at 
that location over the five-minute interval.
The IDL program was further used to visualize the total events in a designated 
region of interest (ROI). In order to compare the radioactivity contained in the tissues of 
interest, we normalized the values by expressing the ROI data as a percentage of the total 
injected dose (%ID) as defined by an ROI with 2880 pixels covering the entire body of 
the mouse. Tumors and glands of interest were analyzed with rectangular or square ROIs
Figure 2.1. The second generation compact gamma 
camera developed for biomedical imaging 
applications.
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of variable pixel dimension to contain the entire area of interest, while excluding nearby 
organs such as the heart, thyroid, or salivary glands. In addition, baseline radioactivity 
was subtracted within the ROI to derive the actual size and morphology of the tissues of 
interest. The baseline radioactivity was defined as the mean value of radioactivity in a 
four-pixel ROI that was placed over an area either in the abdomen or thorax that had a 
constant level of radioactivity throughout the imaging period. Tumor size was calibrated 
for each of the five minute timecuts as the total number of non-zero pixels in the tumor 
region after baseline radioactivity was subtracted (negative pixels were set to zero). The 
final tumor size (in pixels) was established during the 50-55 minute timecut, but the time 
to reach maximum size could occur at early or later times. This time frame was selected 
because some tumors continued to accumulate isotope throughout the imaging period. 
The total counts within the baseline radioactivity corrected ROIs were regarded as the net 
uptake of isotope, and were visualized as 13-level contour maps corresponding to the 
actual radioactive count matrices.
Difference Plots
Contour plots of the difference between raw tumor ROIs without threshold 
deduction were used to measure the changes in radioactivity that occurred within a tumor 
over time. Differences were analyzed with raw tumor ROIs between three different time 
intervals: 0-5 min vs. 5-10 min, 25-30 min vs. 30-35 min, and 50-55 min vs. 55-60 min. 
The difference between each set of tumor ROIs was calculated by subtracting the earlier 
raw tumor ROI from the later. The total difference values were then compared. The 
absolute positive and negative values for these “difference ROIs” were also visualized as
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both a positive plot (counts increase over time) and a negative plot (counts decrease over 
time). A radioactive region in a positive difference plot represents radioiodine 
accumulation while the negative plot represents loss of radioactivity for the location 
within that time period.
Specimen Fixation and Whole Mount Immunofluorescence
Following the imaging process, selected mice were euthanized with an overdose 
of sodium pentobarbital. In order to preserve specimen orientation, silk surgical string 
was threaded through tumor tissues to identify medial, lateral, anterior, and posterior 
regions. Tissues were excised and fixed in 4% paraformaldehyde between 2-12 hours at 
4°C. After fixation, tissues were rinsed in phosphate buffered saline (PBS) and stored at 
4°C. The whole-mount immunofluorescence technique used in this study was slightly 
modified from (Johnstone et al., 2000; Sillitoe and Hawkes, 2002). All incubations were 
performed with gentle agitation and wash periods were refreshed every hour unless 
specified below. Tissues were permeabilized with Triton-X-100 in PBS and non-specific 
binding was blocked with 2% serum in PBS for 6-8 hours. Tissues were incubated with 
0.5 to 3 pg/mL polyclonal IgG rabbit anti-rat NIS (Alpha Diagnostic Int, San Antonio, 
Texas) primary antibody for 60 hours at 4°C, and then rinsed with blocking solution for 4 
hours. Control tissues were incubated in blocking solution. All tissues, including 
controls, were incubated with 0.5 to 2 pg/mL fluorescent goat anti-rabbit Alexa 488 
secondary antibody (Invitrogen, Eugene, Oregon) overnight at 4°C followed by rinsing in 
blocking solution for 4 hours. Bright field and fluorescein filtered photos were captured
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with an Olympus MagnaFire DP71 digital camera and overlay images were created using 
Adobe Photoshop CS3 extended.
Immunohistochemistry
Cryosectioned specimens were placed in a humidified chamber to prevent drying 
and incubated for one hour with 2% Bovine Serum Albumin (BSA) + PBT to block non­
specific immunoglobulin binding. Once the blocking procedure was completed the 
specimens were incubated with a specific primary antibody including: polyclonal IgG 
rabbit anti-rat NIS (Alpha Diagnostic, Inc., San Antonio, TX), polyclonal IgG rabbit anti­
mouse Amphiregulin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or polyclonal 
IgG rabbit anti-mouse HIF-la (R&D Systems, Inc., Minneapolis, MN). Antibody 
concentrations ranged from 2 to 5 pg/mL. Tissues were incubated in the primary 
antibody at room temperature for two hours. Control specimens were incubated in 
blocking solution. Following the primary incubation the diluted antibody solution was 
stored at 4°C for subsequent usage not exceeding four incubations. The specimens were 
rinsed in a series of five two-minute washes in blocking solution.
Sectioned tissues were incubated in an Alexa fluorescent-labeled secondary 
antibody, goat anti-rabbit Alexa 488 or goat anti-rabbit Alexa 555 (Invitrogen, Eugene, 
OR), diluted in blocking solution at room temperature for one hour in a dark humidified 
container. Secondary antibody concentrations ranged from 1 -  5 pg/ml. Specimens were 
rinsed in a series of five two-minute washes in PBT.
Excess PBT was tapped off and slides were mounted with nuclear stain 
Vectorshield with DAPI (Vector Laboratories, Burlingame, CA) and dried at 4°C for two
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hours or until photographed. Immunofluorescent tissue sections were photographed with 
an Olympus 1X50 inverted fluorescent microscope equipped with an Evolution MP 
digital camera using fluorescein (488 nm) or rhodamine (555 nm) depending on the 
secondary antibody. UV filtered light was used also for DAPI visualization. Composite 
figures of fluorescent and DAPI images were created using Adobe Photoshop CS3 
Extended Version 10.
Apoptosis and Necrosis Staining
Cryosectioned mammary tumors were stained for apoptosis and necrosis 
using a kit (Biotium Inc, Hayward, CA) and performed per manufacturer’s instructions. 
Briefly, tissues were rinsed two times for 10 minutes in lx Annexin V binding buffer 
provided in the kit. Following the wash, tissues were stained with a combination staining 
solution provided in the kit targeting Annexin V (apoptosis) and dye Ethidium 
Homodimer III (stains DNA). Tissues were incubated with the staining solution for 10 
minutes and subsequently rinsed with lx  binding buffer. Tissue Slides were coverslipped 
and imaged with Olympus MagnaFire DP71 digital camera and overlay images were 
created using Adobe Photoshop CS3 extended.
Statistics
Images of PyVT tumors from immunohistochemistry and tumor contour plots 
were converted to 32-bit grayscale and pixel luminescence was calibrated using ImageJ 
1.40g. The PyVT immunohistochemical images were resized to the scale of the contour 
plot image for analysis. Statistical analysis consisted of Student’s t-test and Principle
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Component Analysis (PCA) which were performed using Statistical Package for the 
Social Sciences (SPSS) software. Factor variables that were considered for the PCA test 
were as following: the age of the animal (in years) at the time of imaging; the body 
weight of the animal (in grams) prior to imaging; the number of identified tumors in each 
animal; the size of the tumor (as determined at 55 min into the imaging session); the 
percent of injected dose of radioiodine the tumors accumulated (overall tumor 
accumulation at 55 min into the imaging session); the uptake pattern of the tumor (center 
to edge = 1, multi-spot = 2, and ring =3); the location of the primary tumor ( cervical =1, 
upper thoracic =2, lower thoracic =3, inguinal =4, and abdominal =5); and the pregnancy 
status of the animal (pregnant =1 and never pregnant =0). All PCA variables were scale 
values except for pregnancy, tumor pattern, and tumor location which were nominal 
values. Linear regression analysis was used to evaluate possible correlations between 
selected data sets. Data was considered statistically significant at the 95% (p<0.05) 
confidence level.
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CHAPTER 3
RESULTS
MMTV Tumor Distribution
For the current study 58 MMTV mice with a total of 88 tumors were imaged and 
analyzed. Within this population the majority of mice presented one (n=36, 62%) or two 
tumors (n=18, 31%) at the time of imaging, and in very few cases (n=4, 7%) more than 
two tumors were imaged (Fig. 3.1a). Tumor formation on the left side (n=47, 53%) of the 
body was slightly more than on the right side (n=41, 47%) with the majority of tumors 
manifesting in the thoracic mammary glands (n=56, 64%) compared to other gland 
locations (Fig. 3.1b).
MMTV mice bearing multiple tumors (n=22, 38%) represent over half of the 
tumors (n=50, 57%) analyzed in this study. In cases where multiple tumors are present 
there is a bias toward tumor development in the left thoracic (n=16, 73%), right thoracic 
(n=13, 59%), and right inguinal (n=12, 55%) mammary glands compared to the left 
inguinal (n=6, 27%) location. Also, mice bearing multiple tumors have a slight bias for 
the largest tumor presented at the time of imaging to be located the right thoracic (n=8, 
36%), left thoracic (n=6, 27%), and right inguinal (n=5, 23%) glands compared to the left 
inguinal (n=3, 14%) mammary gland location.
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Imaging Radioiodine Uptake In Vivo Correlates with NIS Protein Expression in 
Normal Mammary Glands and Mammary Tumors of the MMTV and PyVT Models
In order to validate the efficacy of the gamma camera to detect functional NIS 
activity in vivo, NIS protein expression was analyzed by immunohistochemistry (IHC) in 
normal mammary and mammary tumor tissues. The initial step was to validate whether 
the gamma camera could detect functional NIS and radioiodine uptake in mammary 
glands under non-tumor conditions. Studies have shown that NIS is expressed and will 
transport radioiodine during lactation (Cho et al., 2000; Tazebay et al., 2000). Therefore, 
mice (n=6) from a low mammary tumor incidence strain, C57BL/J6 (Freund et al., 1992), 
were imaged at three different stages of normal mammary development, which included 
the nulliparous (virgin) mouse (n=2), the lactating mouse (n=2), and the multiparous 
(previously lactating) mouse (n=2) mammary stages (Fig. 3.2). Following the imaging 
process the nulliparous (n=5), lactating (n=4) and multiparous (n=5) mammary glands 
were analyzed for NIS expression. The gamma camera detected significant (p<0.01) 
radioiodine accumulation only during the lactating stage of mammary development (Fig. 
3.2d) which was verified with IHC localization of NIS (Fig. 3.2b). Also, there was no 
radioiodine accumulation visualized in the mammary glands of nulliparous or 
multiparous mice which was further supported by negative IHC findings (Fig. 3.2a and 
c).
MMTV tumors also accumulate radioiodine throughout the imaging period which 
implicates functional NIS activity. NIS protein expression was analyzed via IHC in 
MMTV tumors (n=18) and detectable levels of NIS protein were demonstrated. These 
NIS locations were coincident with the locations of radioiodine uptake in the gamma
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images of tumors (example in Fig. 3.3a). Unexpectedly, during the imaging session of a 
nulliparous MMTV tumor bearing mouse the gamma camera detected elevated 
radioiodine accumulation in a seemingly normal mammary gland (Fig. 3.3b). At 
necropsy, a small (3 mm) non-palpable tumor was located at the end of the mammary 
gland (Fig. 3.3bl). IHC localized NIS protein in the tumor which was coincident with the 
radioiodine accumulation pattern detected by the gamma camera.
In order to reaffirm that radioiodine accumulation was a function of NIS 
expression in the PyVT model, the protein was localized in tumor tissue using an anti- 
NIS antibody via indirect immunohistochemistry (Fig. 3.4). The left inguinal tumor was 
excised and assessed for NIS whole mount expression (Fig. 3.4b-d). Both the gamma 
image and NIS protein were highly associated (Fig. 3.4e).
Three dimensional gray scale luminescence models were made for both the 
contour plot, made from a region of interest (ROI) around the tumor in the gamma image, 
and the fluorescent NIS optical image (Fig. 3.5). The contour plot (Fig. 3.5a) provided 
topographical data of the ROI gamma counts from radioiodine within the tumor at the 50- 
55 minute time cut which was our best estimate of overall tumor size. The three 
dimensional images of both the contour plot and optical fluorescent image (Fig. 3.5b) 
were also highly similar. However, the optical protein localization intensity suggested 
that there was more NIS protein in the lower part of the tumor compared to the intensity 
of the amount of radioiodine that accumulated in the same area.
In early PyVT tumorigenesis (Fig. 3.6) gamma imaging detected localized areas 
with increased radioiodine accumulation in the inguinal mammary glands. However, 
upon whole mount localization for NIS protein (Fig. 3.6b-d), there appeared to be
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discrete expression patterns for NIS during early tumorigenesis that the gamma camera 
can detect, but with less resolution. The high power (7x) localization suggests that NIS is 
expressed in isolated groups of cell clusters (Fig. 3.6f). The apparent amalgamation of the 
radioiodine uptake within these cluster groups appeared on the gamma camera as a 
compact area of uptake. This further supports the applicability of the gamma camera to 
detect early tumorigenesis in the PyVT model with radioiodine targeting of NIS function.
In Vivo Screening for PyVT Mice and Mammary Tumors Using Gamma Imaging
At parturition approximately 25% of female progeny carry the PyVT transgene 
based on Mendelian genetics (Guy et al., 1992). In order to non-invasively identify 
which individuals were transgenic, pups were screened using the gamma camera. By five 
weeks pups were selected at random (n=6) from candidate litters and injected with 0.52
19 S ioc #MBq (14 pCi) Na I. Fifty minutes after Na I administration, pups were imaged supme 
for 10 minutes. By screening individual animals, wild type mice (Fig. 3.7a) and PyVT 
candidates (Fig. 3.7b) were identified based on radioiodine accumulation in nulliparous 
mammary glands. To ensure that the radioiodine uptake was not solely in response to 
mammary maturation due to endocrine stimuli, PyVT candidates were re-imaged a week 
later and continued to incorporate radioiodine in the mammary glands (Fig. 3.7c). In all 
cases mice identified as PyVT candidates from in vivo screening developed palpable 
tumors in all mammary glands which were detected with radioiodine gamma imaging 
(Fig. 3.7d).
A measure of the percent injected dose of radioiodine was assessed between all
wild type and PyVT screened mammary glands. PyVT individuals exhibited greater
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radioiodine accumulation in a minimum of three mammary gland locations compared to 
wild type siblings (Fig. 3.8a, PyVT marked with *). Further analysis indicated that the 
overall mammary gland radioiodine accumulation in PyVT animals was significantly 
greater (p<0.01) than the mammary glands of wild type siblings (Fig. 3.8b).
The Unique Biodistribution of Radioiodine in MMTV Tumors
Region of interest analysis of MMTV tumors revealed that the biodistribution of 
radioiodine could be classified into three discrete patterns of uptake. The first uptake 
pattern in which MMTV tumors (n=28) would accumulate radioiodine was a “center to 
edge pattern”. This pattern was characterized as a central active core which becomes less 
intense toward the edge of the tumor (Fig. 3.9a). The second pattern classification was 
the “multi-spot pattern” which was most prevalent (n=63) in MMTV tumors. The multi­
spot pattern was characterized as having multiple centers within the tumor that were 
active (Fig. 3.9b). The final classification type was a special multi-spot pattern called the 
“ring”. This pattern was rarely observed in MMTV tumors (n=5) and was characterized 
because the tumor center shows less activity than the surrounding edges (Fig. 3.9c).
Relationship Between Tumor Size, Uptake Patterns, and Radioiodine Accumulation 
in MMTV and PyVT Tumors
In order to assess a possible relationship between radioiodine uptake patterns and 
tumor size or the radioactive dose tumors would accumulate, tumors falling into a 
specific classification were compared. Using Student’s t-test the uptake patterns were 
significantly (p<0.01) correlated with tumor size in all groups (Fig. 3.10a). When
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compared with the percent injected dose, the uptake patterns significantly (p<0.01) 
correlated with center to edge and multi-spot groups, however the ring group was not a 
significant (p>0.05) distinguishable from the multi-spot group (Fig. 3.10b).
Once we established that the radioiodine uptake patterns correlated with tumor 
size and percent injected dose from box plot analyses, all three categories were plotted 
together and the data indicate that tumor size correlates with overall total radioiodine 
accumulation in a MMTV tumor (Fig. 3.11a). The data further suggested that the center 
to edge pattern was present in smaller (less than 75 pixels), with less total radioactivity. 
By comparison, the multi-spot pattern exists throughout the entire tumor size range, but is 
predominant in larger (greater than 75 pixels) tumors. The ring pattern was 
predominantly associated with very large (>200 pixels) tumors. At the pixel level, which 
is as close to the cellular level as the gamma camera can resolve radioiodine, the center to 
edge and ring pattern tumors continued the same overall trend of more radioactivity 
associated with increased tumor size (Fig. 3.11b). However, the multi-spot tumor pattern 
showed no correlation between tumor size and per pixel radioactivity.
Based on the correlation data in figure 3.11, there appeared to be two trends of 
radioiodine uptake across various sized tumors. The first “High” trend can be represented 
tumors that accumulated high levels of radioiodine with increased tumor size. The second 
“Low” trend is characterized by tumors that only reached a low plateau of radioiodine 
with increased tumor size. These trends were most obvious at the pixel level (see Fig. 
3.11b).
From the entire tumor data set, three groups (ten tumors in each group with 
similar size) were randomly selected from small, moderate, and large tumors (Fig.
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3.12.1). Within each cohort group the first 30 minutes of the radioiodine uptake was 
averaged to get one “high” trend and one “low” trend and the rates of uptake were 
compared between each groups. The small tumor cohort (Fig. 3.12.2a) had a rate of 
radioiodine accumulation 1.5 times greater in the “high” trend group compared with the 
“low” trend. In the moderate and large tumor cohort (Fig. 3.12.2b and c), the rate of 
radioiodine accumulation was two times greater in the “high” trend groups compared 
with the “low” trends. These data suggest that tumors within the moderate to large size 
range that have similar uptake patterns could be grouped separately based on the rate of 
radioiodine accumulation.
A principal component analysis (PCA) was used as a guide to observe how 
coherently the variables collected at the time of imaging related to overall MMTV 
tumorigenesis. Eight variables were considered in the PCA test including: age, body 
weight of the mouse, tumor size, percent of radioiodine accumulated in the tumor, uptake 
pattern, pregnancy, tumor location on the body, and the number of tumors presented. 
Three principal components were extracted from the data variables which explained 64% 
of the total variance between the variables. The three components extracted were the 
percent injected dose component (PC 1), the pregnancy component (PC 2), and the gland 
location component (PC 3). These components were named based on the highest scoring 
component coefficient (TABLE 3.1), which represented the weights used to compute the 
factor scores to each variable. The extracted components also indicated which variables 
were correlated along with the principal components (Fig. 3.13).
The first component, the percent injected dose, was highly correlated with tumor 
size (Fig. 3.14a) which validated our previous findings (Fig. 3.11a). The second
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component, pregnancy, was negatively correlated with animal age, which suggested that 
MMTV animals with tumors were more likely to be young and pregnant/previously 
pregnant or older virgin mice (Fig. 3.14 b). Pregnancy also correlated with the number of 
tumors an animal had at the time of imaging. These data suggested that in the MMTV 
model parity increased the likelihood of both tumor formation and the number of tumors 
that would manifest (Fig. 3.15a). The third component, mammary gland location, was 
correlated with the animal’s body weight. In the MMTV model it appeared that larger 
tumors, which would also contribute to overall body weight, were located in the lower 
thoracic and inguinal/abdominal regions of the body (Fig. 3.15b).
Nine PyVT mice with twenty-six tumors in total were sorted into two groups 
based on the way they accumulated radioiodine over the hour imaging period. The first 
group was the center to edge pattern which is characterized by a central hot mass 
spreading out towards the edge of the tumor. The second group was the multi-spot pattern 
with multiple areas within the tumor that are active. A comparison between the two 
groups shows that there was a significant (p<0.01) difference both in terms of tumor size 
(pixels) (Fig. 3.16a) and the overall percent of the injected dose that these tumors 
accumulated (Fig. 3.16b). This suggests that the uptake patterns are uniquely different 
and can be used as predictors of tumor size and radioactivity.
Further analysis comparing tumor size (in pixels) at the 50-55 minute time cut, the 
percent injected dose, and tumor uptake patterns indicated that there was a positive 
correlation between the size of the whole PyVT tumors and the percent of the injected 
dose these tumors accumulated (Fig 3.17a). Also tumors falling into the center to edge 
125I uptake pattern were predominant in small tumors (<50 pixels). At the pixel level,
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which is as close to the cell level as the gamma camera can detect there was no 
relationship between the size of the tumors and radioactive dose (Fig 3.17b). This 
suggests that in the PyVT model there is a uniform accumulation rate throughout the 
tumor at the pixel level.
Difference Plots
The difference plots revealed specific areas within each tumor that were actively 
incorporating (Fig. 3.18, color scale) or not incorporating (Fig. 3.18, grayscale) 
radioiodine at the beginning (Fig. 3.18a), mid-point (Fig. 3.18b) and end (Fig. 3.18c) of 
imaging sessions. There was profound heterogeneity in these accumulation patterns 
throughout the MMTV population, but these plots suggested that the greatest amount of 
activity change in tumors occurred during the first 10 minutes of the imaging session 
immediately following radioiodine administration (Fig. 3.18a). Areas that continue to 
accumulate radioiodine throughout the imaging session were generally next to or within 
the area that was originally very active. Negative difference plots indicated that
radioisotope loss within the tumor occurred primarily in the last half of imaging (Fig.
3.18b and c). The data indicate that the majority of tumors (n=63 out of 88) lose
radioisotope toward the end of the imaging session.
The yellow arrows in Fig. 3.18a, b, and c represent a presumed pathway of 
radioiodine transfer in a mammary tumor. The suspected pattern indicates that 
radioiodine transfer occurred from the outer edge of the tumor toward the central mass of 
the tumor. In some cases areas of active radioiodine uptake and loss correlate with the
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expression patterns of NIS (Fig. 3.18d) suggesting that the difference plots may provide 
critical information about the sites within the tumor where functional NIS is expressed.
In Vivo Imaging of MMTV and PyVT Tumor Growth and Development
Repetitive in vivo gamma imaging can possibly be employed for targeting the 
molecular signatures of tumors for longitudinal studies lasting throughout tumor 
development. In order to determine whether tumor growth and development displayed 
unique signatures that could be assessed with the gamma camera, a subset of the MMTV 
population (n=7) were imaged two (n=5) or three (n=2) times. Between each imaging 
session the overall change in tumor size (in pixels) was calculated and divided by the 
time lag (in days) between imaging sessions to calculate tumor growth rates (TABLE 
3.2). There were two cases (mice 4 and 6) of apparent tumor size reduction, but the 
growth rate for these two animals was not significant (p>0.05). The rest of the tumors 
analyzed (n= ll) all increased in size. However, no correlation between tumor growth 
rates and the initial size, location and pattern of the tumor was detected. In two cases 
(mice 5 and 7) there was a change in radioiodine uptake in subsequent imaging sessions. 
In both circumstances a center to edge tumor pattern was identified as a multi-spot 
pattern accumulation pattern by the next imaging session. There were no cases of multi­
spot pattern tumors changing their pattern of radioiodine uptake which further suggests 
that the center to edge pattern appears specific to smaller tumors.
Early screening for PyVT mice identified individuals, in the population as 
candidates to track and monitor for early tumor progression. In figure 3.19a the right 
thoracic tumor was analyzed as early as five weeks of age, and there was a shift from a
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center to edge pattern (figure 3.19al) when the tumor was first detected to a multi-spot
pattern on subsequent imaging sessions (Fig. 3.19a2 and Fig. 3.19a3). There was a
positive correlation with the size of the tumor and the amount of the radioiodine dose the
tumor accumulated as seen previously in (Fig. 3.17a), but at the pixel level monitoring
tumor progression had a negative correlation (Fig. 3.19b) which implies that 125I transport
in groups of cells decreases with tumor progression. This was a point of difference
compared to the finding in (Fig. 3.17b) that there was no relationship and uniform
1
cellular ability to accumulate I.
1 7^MMTV Tumorigenesis Influences I Accumulation in the Mammary Glands
During the imaging process many apparently non-tumor mammary glands were 
observed to accumulate radioiodine when a primary MMTV tumor was present in the 
animal. Previous studies have reported that normal radioiodine accumulation occurs in 
mammary glands during lactation (Tazebay et al., 2000; Wapnir et al., 2003; Zuckier et 
al., 2001), which was further validated by this study using the gamma camera. In addition 
to this expected finding, the imaging data here suggest that the majority of MMTV mice 
also accumulate radioiodine in one (n=50, 87%) or two (n=43, 75%) mammary glands 
which were not originally detected as the site of the primary tumor.
NIS protein expression was analyzed for mammary glands (n=16) that 
accumulated radioiodine but were not specified as the site of the primary tumor based on 
gamma imaging. The majority of these glands (n=12, 75%) that were analyzed for NIS 
expression were positive by immunohistochemistry. In Fig. 3.20, the inguinal mammary 
gland was analyzed for NIS expression in a mouse with a mammary tumor (Fig. 3.20a)
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and a different mouse happening to develop a non-mammary tumor (Fig. 3.20b). In both 
cases there were detectable levels of radioiodine accumulation identified by the gamma 
camera imaging which correlated with the localization of NIS protein in the mammary 
glands (Fig. 3.20a3 and b3). Moreover, these data suggest that the presence of a tumor 
(mammary based or not) influences the biology of non-involved mammary glands to 
become receptive to radioiodine accumulation.
Comparisons of the Radioiodine Accumulation in Spontaneous (MMTV) and 
Transgenic (PyVT) Tumor Models
Once it was confirmed that the gamma camera was also capable of imaging 
mammary tumors in the PyVT model, a comparison was made between the overall 
radioiodine uptake patterns in transgenic mice compared with those observed in 
spontaneous MMTV animals. Since PyVT mice (n=9) develop tumors in all mammary 
glands, these animals were compared with MMTV mice (n=ll) also bearing more than 
one tumor to control for radioiodine signal dispersal in multiple mammary tumor sites. A 
fixed region of interest (ROI) (9 pixels) was placed over the hottest area of uptake in all 
mammary tumors and analyzed for the percent injected dose of radioiodine. Figure 3.21a 
shows that the size range of tumors was similarly distributed for both MMTV (n=24 
tumors) and PyVT (n=26 tumors) mice. Student’s t-test further supported that the average 
tumor size was not significantly (p=0.65) different between the two groups. Similar 
distributions control for tumor size in both groups that could bias radioiodine 
accumulation measurements since we have shown that tumor size and radioiodine 
accumulation are related (see Fig. 3.17a). The overall average percent injected dose of
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radioiodine in the PyVT model was significantly (p<0.01) more than the spontaneous 
MMTV model bearing multiple tumors (Fig. 3.21b). Interestingly there is also a factor of
1 9Stwo greater average rate of I accumulation in the PyVT model compared to the average 
rate in the MMTV model.
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Figure 3.1. (a) The distribution o f MMTV mice used for the in vivo gamma imaging project and the 
number o f tumors presented at the time o f imaging, (b) The distribution o f MMTV tumors and the 
mammary gland site o f tumorigenesis.
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Figure. 3.2. (a) Nulliparous mouse shows no 125I 
uptake in the left inguinal gland (arrow and a l ex 
vivo) and no NIS protein localization (a2 and 
overlay a3). (b) Lactating mouse shows uptake in 
the left inguinal gland (arrow and b l ex vivo) 
which correlates with NIS protein localization 
(green signal in b2 and overlay b3). (c) 
Multiparous mouse shows no 125I uptake in the 
left inguinal gland (arrow and cl ex vivo) and no 
NIS protein localization (c2 and overlay c3). (d) 
Average percent injected dose as measured by the 
gamma camera indicates significant (p<0.01) 125I 
uptake during lactation compared to other normal 
mammary gland states. (Thy = thyroid, Sal = 
salivary gland, Sto = stomach, Bla = bladder, Mgl 
= mammary gland, Inj = injection site)
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Figure 3.3. (a) Gamma camera detects 125I uptake in a MMTV left inguinal primary tumor (al). The 
primary tumor (a2 ex vivo) also localizes NIS protein in the non-necrotic portion o f the tumor (green signal 
in a3 and a4 overlay). Both the l25I accumulation and NIS protein localization are highly associated (a5 
arrow), (b) The gamma camera can detect MMTV tumors at an early stage o f tumorigenesis. The right 
inguinal tumor (b l, Tum2) was detected based on elevated 125I accumulation. NIS protein was localized in 
the secondary tumor (b2 ex vivo) predominantly in the 3 mm tumor at the end o f the mammary gland (green 
signal in b3 and b4 overlay). A composite o f the gamma image and the NIS immunohistochemistry image 
o f the small tumor are highly similar (b5 arrow). (Thy = thyroid, Sal = salivary glands, Sto = stomach, Bla 
= bladder, Inj = injection site, Mgl = mammary gland, Turn = tumor)
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Figure 3.4. (a) PyVT gamma image from a sixty minute imaging session, (b) Brightfield image o f the left 
inguinal tumor (arrow a), (c) Indirect whole mount NIS localization in the left inguinal tumor (green signal) 
using an anti-NIS primary antibody, (d) Overlay image o f the bright (b) and fluorescent (c) images 
identifying the areas in the tumor where NIS is expressed, (e) An overlay o f the PyVT gamma image (a) 
with NIS localization (c). The NIS image was scaled down and mimics the radioiodine trend seen in the 
gamma image (arrow, yellow signal). (Turn = tumor; Inj = injection site; Sto = stomach)
Figure 3.5. (a) Gray scale three dimensional pixel luminescence profile o f the 50-55 minutes time cut 
contour plot o f the gamma image for the left inguinal tumor, (b) Gray scale three dimensional pixel 
luminescence profile o f fluorescent NIS localization in the left inguinal tumor, (inset luminescence scale)
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Figure 3.6. NIS expression patterns in an early PyVT tumor, (a) The gamma image o f early tumorigenesis 
in a PyVT mouse with 125I accumulation in all mammary gland sites, (b) Ex vivo bright field image o f the 
right inguinal gland (#4 R upper, with early lesions) connected to the right abdominal tumor (# 5 R, lower), 
(c) NIS localization indicates discrete expression patterns in the inguinal gland, and more significant 
staining in the abdominal tumor area, (d) Overlay image o f (b) and (c). (e) Overlay o f NIS localization (c) 
and the gamma image (a) suggests that the discrete pattern of NIS expression was detectable in the gamma 
image as a localized area o f activity, (f) A 7x view o f the acini expression patterns of NIS in the right 
inguinal mammary tumor (#4 R). (Thy = thyroid, Sal = salivary glands, Sto -  stomach, Bla = bladder, Inj = 
injection site, # 2/3 = thoracic tumors, # 4 = inguinal tumors, # 5 = abdominal tumors)
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Figure 3.7. Example o f gamma camera screening of the PyVT model with 125I. (a) A 10 min. screen 
identifying a wild type FVB/N littermate showing no mammary accumulation at 5 weeks, (b) A 10 min. 
screen at 5 weeks identifying a PyVT mouse showing 125I accumulation in the right thoracic mammary 
gland, (c) One hour imaging of PyVT mouse (b) at 6 weeks with accumulation in putative tumor mammary, 
but uptake was evident in other glands as well, (d) One hour imaging o f PyVT mouse (b and c) at 16 weeks 
with mammary tumors in all glands. (Thy = thyroid, Sto = stomach, Mgl = mammary gland, Turn = tumor, 
Inj = injection site, Bla = bladder)
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Figure 3.8. PyVT mammary gland l25I uptake from screening studies, (a) Radioiodine accumulation in all 
mammary glands o f mice screened for PyVT transgene expression (Mice 314-316 screened at 5 weeks and 
Mice 327-329 screened at 7weeks). (b) Overall radioiodine uptake was significantly different (p<0.01) in 
PyVT mice compared to wild type siblings.
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Figure 3.9. Contour plots o f the three types o f ,25I distribution observed in MMTV tumors at three different 
times during the imaging period (the left panel measures at 0-5 min, the center panel measures at 25-30 
min, and the right panel measures at 55-60 min). (a) A center to edge accumulation pattern characterized by 
a central active core which spreads to the tumor edges, (b) A multi-spot pattern characterized by many 
active areas within the tumor, (c) The ring pattern is characterized as a special case o f multi-spot in which 
the core of the tumor is less active than the surrounding edges o f the tumor.
48
a Coinparision B etw een  MMTV Tumor S ize s  and Na125l Accum ulation Patterns
400-
300-
2  200 -
100 -
y      | |
Center to Edge Multi-Spot Ring
MMTV Tumor Na125l A ccum ulation Patterns
Coinparision B etw een  MMTV Tum or Na125l R entention and A ccum ulation Patterns
S3 10-
20-
15-
I I I
Center to Edge Multi-Spot Ring
MMTV Tumor Na125) Accum ulation Patterns
Figure 3.10. (a) Box plot analysis, comparing MMTV tumor size with the three radioiodine accumulation 
patterns, indicates that each uptake pattern is a significant (p<0.01) to specific tumor size ranges, (b) Box 
plot comparison between the three radioiodine accumulation patterns and the percent o f injected dose for 
MMTV tumors suggests that the center to edge and multi-spot uptake patterns significantly (p<0.01) 
predict radioactivity in tumors. The percent injected dose between the multi-spot and ring pattern was not 
significant (p>0.05). (The dots represent outliers.)
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MMTV Tumor S ize  and Radioactivity Compared with Na125l Accum ulation Patterns
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Figure 3.11. (see next page for caption)
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Figure 3.11. (see previous page for figure) (a) MMTV tumor size positively correlates with tumor 
radioactivity based on the percent o f injected dose taken in by tumors (R2 = 0.581). The correlation further 
supports the box plot analysis (Fig. 3.10) suggesting that center to edge accumulation pattern predominates 
in small, less active tumors, (b) At the pixel level, center to edge pattern (R2 = 0.539, solid line) tumors also 
positively correlate with tumor size and percent injected dose. The multi-spot pattern (R2 = 0.142, dotted 
line) tumors appear to have no correlation between size and radioactivity. The ring pattern (R2 = 0.332, 
dash line) tumors have a slight correlation between tumor size and radioactivity.
MMTV Tumor Accumulation Patterns Compared with Tumor Size 
and Radioactivity 
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Figure 3.12.1. Based on the correlation data in Fig. 3.11, there appeared to be two trends o f 125I uptake as 
tumors increased in size. Three groups (ten tumors in each group) were selected from small (green), 
moderate (blue), and large (red) tumors and each cohort had to have similar size range. Trend 1 or “High” 
trend (green, blue or red data points without a black outline) was a steady increase in l25I uptake regardless 
of size. Trend 2 or “Low” trend (green, blue or red data points with a black outline) was a plateau or 
decrease in 125I uptake as tumor size increased.
Figure 3.12.2. (see next page for figure) Each cohort’s dynamic I25I uptake was averaged based on the 
High or Low trend (described in Fig. 3.12.1) within the first 30 minutes o f their imaging period, (a) Small 
tumors (60-80 pixels) average 125I accumulation were significantly (p<0.05) higher and the rate of 
accumulation was 1.5 times greater in the high trend group compared to the low trend group, (b) Moderate 
tumors (100-140 pixels) average l25I accumulation were significantly (p<0.05) higher and the rate of 
accumulation was two times greater in the high trend group compared with the low trend group, (c) Large 
tumors (140-250 pixels) average 125I accumulation were significantly (p<0.05) higher and the rate of 
accumulation was also two times greater in the high trend group compared with the low trend group.
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TABLE 3.1. Component Scores for Extracted Components
Component
1 2 3
Age -.035 -.410 .025
Weight .055 -.020 .476
T umor # -.062 .399 .247
Pattern .280 -.038 .159
Tumor %ID .435 .048 -.241
Gland -.128 -.023 .621
Pregnancy .083 .587 -.194
Size .410 .048 -.017
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization. 
Component Scores.
MMTV Component Plot in Rotated Space
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Figure 3.13. Clustered variables based on the coefficient matrix in TABLE 3.1. Three components were 
extracted: the percent o f the injected dose tumors accumulated; the pregnancy component; and the location 
o f the tumor at the time o f imaging.
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Figure 3.14. (a) The first component extracted from the PC A test suggested the percent injected dose factor 
scored best with tumor size (see TABLE 3.1, component 1). The graph o f the factor score for component 1 
with tumor size shows that tumor size is correlated with the radioactivity o f the tumor (R2= 0.863), which 
verifies the correlation made previously in Fig. 3.11a. (b) The second component extracted from the PCA 
test was the pregnancy component (see TABLE 3.1, component 2). This component scored negatively for 
the age o f the animal. The graph o f the factor score o f component 2 with age suggests a negative 
correlation with pregnancy (R2 = 0.369); therefore, the data indicate that MMTV tumors were imaged with 
mice who were older and never pregnant (left half o f the graph) or with mice who were younger and 
pregnant/previously pregnant.
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Figure 3.15. (a) The second component extracted from the PC A test was the pregnancy component (see 
TABLE 3.1, component 2). This component scored well with the number o f tumors presented during the 
time o f imaging. The graph o f the factor score o f component 2 positively correlates pregnancy with overall 
number o f primary tumors (R2= 0.401), which suggests that pregnant MMTV mice (right side o f the graph) 
are more likely to develop multiple tumors compared to nulliparous mice, (b) The third component 
extracted from the PCA test was the mammary gland component or the location o f the primary tumor (see 
TABLE 3.1, component 3). The component scored well with the body weight o f the animal. The graph 
indicates that there is a positive correlation with the body weight o f the animal and the location o f the 
primary tumor (R2= 0.439). These data indicate that tumors in the lower thoracic and inguinal (right side of 
the graph) locations o f the body contribute more to the overall body weight o f the animal at the time of 
imaging.
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Figure 3.16. (a) Box plot analysis, comparing PyVT tumor size with two radioiodine accumulation 
patterns, indicates that the uptake pattern is a significant (p<0.01) predictor o f tumor size, (b) Box plot 
comparison between two radioiodine accumulation patterns and the percent o f injected dose for PyVT 
tumors suggests uptake patterns significantly (p<0.01) predict radioactivity in tumors as well. (The single 
dot represents an outlier within the center to edge group.
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Figure 3.17. (a) PyVT tumor size positively correlates with tumor radioactivity based on the percent o f 
injected dose taken in by tumors (R2 = 0.791). The correlation further supports the box plot analysis 
(Fig.3.5) suggesting that center to edge accumulation pattern predominates in small, less active tumors, (b) 
At the pixel level, center to edge (R2 = 0.064, dotted line) and multi-spot (R2 = 0.008, solid line) tumors 
appear to have no correlation between tumor size and radioactivity, which suggests a uniform radioiodine 
distribution in the cells o f both patterns.
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Figure 3.18. Contour plots o f the change in radioactive counts within the MMTV tumor ROI. The color 
contour plots represent the gain o f counts within the five minute time span. The gray scale contour plots 
represent the loss o f counts within the same time span, (a) The 0-5 min vs. 5-10 min difference plot shows 
that early in the imaging period the tumor accumulates 125I as it is presented, (b) The 25-30 min vs. 30-35 
min difference plot shows more areas within the tumor are losing counts while others continue to gain, (c) 
The 50-55 min vs. 55-60 min difference plot shows the continuation of loss and gain that was demonstrated 
in (b). (d) NIS expression in this tumor shows discrete expression patterns that correlate with areas of 
active uptake in (a), (b), and (c). (The yellow arrows in (a), (b), and (c) represent the presumed pathway of 
125I transfer in a mammary tumor. The pattern shows 125I transfer from the outer edge o f the tumor toward 
the central mass o f the tumor.)
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TABLE 3.2. MMTV Tumor Development Study
Mouse
(tumor
location)
Initial
Tumor
Size
(pixels)
Initial
Pattern
Type
Post
Imaging
(days)
Tumor
Size
(pixels)
Pattern
Type
Change 
in Tumor 
Size 
(Apixels)
Rate of 
Tumor 
Growth 
(Apixels/days)
1 (RT) 13 C-E 7 23 C-E 10 1.4
2 (RI) 22 C-K 4 41 C-E 19 4.8
2 (LT) 39 M-S 4 69 M-S 30 7.5
3 (LI) 35 M-S 7 69 M-S 34 4.9
3 (R 0 v, M-S 7 94 M-S 61 8.7
4 (LT) 31 M-S 6 45 M-S 14 2.3
4 (RI) 68 M-S 6 65 M-S -3 -0.5
5 (RT) 159 M-S 12 407 M-S 248 20.7
5 (LI) 13 C-E 12 23 M-S 10 0.8
6 (R I ) 60 M-S 22 52 M-S -8 -0.4
6 (RT) 52 M-S 27 58 M-S 5 0.2
7 (RT) 24 C-E 14 52 C-E 28 2.0
7 (RT) 52 C-E 21 107 M-S 55 2.6
(RT = right thoracic, RI = right inguinal, LT = left thoracic, C-E = center-to-edge, M-S = 
multi-spot)
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Figure 3.19. (a) Contour plots o f a PyVT mouse imaged three times to monitor the change in tumor 
radioiodine uptake with tumor progression. Radioiodine uptake begins as a center to edge pattern (al), 
which progresses to a multi-spot pattern (a2 and a3). Patterns in (al and a2) have been scaled down in 
relation to final tumor size (a3). (b) Analysis o f PyVT tumor development with regard to tumor size and 
radioactivity in the mammary gland. There was a positive correlation (R2 = 0.996) with tumor size (x-axis) 
and the percent o f radioiodine the tumor accumulated (blue line, y-axis to the left). At the pixel level, which 
represents groups o f cells in the tumor, there appears to be a negative relationship (R2 = 0.531) between 
tumor size (x-axis) and the percent o f radioiodine groups of cells o f the tumor accumulated (red line, y-axis 
to the right).
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Figure 3.20. (a) The gamma image o f a MMTV tumor bearing mouse shows 125I accumulation in 
mammary glands other than the primary tumor (a l). The right inguinal mammary gland (a2 ex vivo) 
contralateral to the primary tumor was analyzed for NIS protein expression (a3). NIS protein localization 
was expressed in discrete patterns throughout the mammary gland (a3 and a4 overlay), (b) The gamma 
image o f a non-mammary tumor shows no 1251 uptake in the tumor but in the left inguinal mammary gland 
below the tumor (Mgl-1 b l and b2 ex vivo). Immunolocalization confirmed that NIS protein was expressed 
in the mammary gland in clusters throughout the mammary gland (b3 and b4 overlay). (Sal = salivary 
glands, Thy = thyroid, Mgl = mammary gland, Turn = tumor, Sto = stomach, Inj = injection site)
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Figure 3.21. (a) For the comparison study, the distribution o f MMTV and PyVT tumors were similar in 
size, (b) The overall average o f the percent injected dose o f 125I in tumors o f both models indicate 
radioiodine accumulation rates were significantly (p<0.01) higher in the PyVT model.
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CHAPTER 4
DISCUSSION
In an effort to address the growing need for effective high-performance imaging 
modalities that are specifically designed for breast cancer imaging we tested our novel 
gamma camera to target the molecular function of NIS in the mammary tumors of 
MMTV and PyVT mice. These results indicated that the immunohistochemical 
expression of NIS was coincident with the patterns of radioiodine biodistribution in 
MMTV tumors as well as in PyVT tumors and normal mammary glands.
NIS expression in PyVT tumors was reported at the mRNA (Kogai et al., 2004) 
and protein level (Knostman et al., 2004), which was further supported in whole mount 
staining for NIS in PyVT tumors presented here. In the three dimensional comparison 
between optical NIS localization and the contour plot (see Fig. 3.5) there appeared to be 
more available NIS protein in the lower portion of the tumor which did not fully correlate 
with the amount of radioiodine accumulated in the same area. In human breast cancer 
there appears to be disparity between NIS expression and actual radioiodine uptake for 
treatment (Beyer et al., 2008; Renier et al., 2009). Specifically, Knostman et al. (2007) 
have found that in MCF7 cells PI3K activation of NIS leads to the expression of 
underglycosylated NIS which cannot traffic to the plasma membrane and PI3K inhibits 
radioiodine uptake of exogenous NIS. Since PyVT tumors both share similar 
morphological characteristics with human breast cancer and frequently have activated
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PI3K pathway, this post translational processing may account for the slight discrepancy 
between the available NIS protein and the amount of radioiodine that was accumulated.
In lieu of performing tail snips for genetic screening, which could cause undue 
harm to neonates, PyVT mice were housed with their wild type littermates in order to 
examine if the gamma camera could identify transgenic mice and in effect image early 
tumor development. According to the study performed by Lin et al. (2003) roughly 60% 
of PyVT mice have premalignant hyperplasias by four to six weeks of age. Therefore, the 
screen at five and seven weeks of age matched well with the proposed critical period. Not 
only was the gamma camera able to screen animals effectively for potential genotype, but 
also very early tumor development was detected at the premalignant hyperplastic stage. 
Continued research is warranted as to the earliest the gamma camera can detect 
transgenic mice. Early screening at three weeks of age, as proposed by (Guy et al.,
1992) when lesion may develop, may further validate the gamma camera’s efficacy, but 
concerns over sedating such young animals will have to be addressed. What is unknown 
is whether the gamma camera can screen male transgenic mice for potential genotype. It 
has been reported that PyVT males do express the transgene and develop 
adenocarcinomas in their mammary glands and testes (Guy et al., 1992), therefore, more 
testing with the gamma camera could resolve whether lesions in the seminal vesicles 
accumulate iodine at detectable levels for male screening. Also for mouse husbandry 
purposes it would be advantageous to identify transgenic males for establishing breeding 
founders.
MMTV tumors have unique distribution patterns of radioiodine uptake that can be 
correlated with overall tumor size and radioactivity. The data indicated that small tumors
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(<75 pixels) were primarily associated with a center to edge uptake pattern and also 
resulted in less total activity accumulation within the tumor. Moderate and large tumors 
(>200 pixels) all were associated with the multi-spot or ring (primarily in very large 
tumors) patterns which were statistically significantly correlated with tumors later in 
development. The observed radioiodine uptake patterns are likely due to not only to NIS 
expression, but also to a range of biochemical processes in the tumor. For example, small 
tumors with the center to edge uptake pattern are solid masses which give the uniform 
pattern. However, when the tumor becomes larger more areas become hypoxic and as a 
result parts of the tumor become necrotic which may contribute to the multi spot patterns 
of radioiodine accumulation and NIS patterning. Preliminary data from a multi-spot 
tumor stained for apoptosis and necrosis suggest that throughout the whole tumor there 
are discrete areas undergoing programmed cell death (Fig. 4.1). Furthermore, analyzing 
the marker associated with the response to hypoxic conditions within the tumor could 
reveal critical information of tumor pathology. H IF-la in relation to NIS expression 
within a multi-spot tumor also suggests that both are expressed in discrete patterns within 
the tumor (Fig. 4.2d-f). Interestingly, whole mount immunolocalization for H IF-la 
indicates that the protein is primarily expressed in putative normal tissues surrounding the 
primary tumor (Fig. 4.3). This supports current literature that suggests H IF-la is 
expressed during tumorigenesis to immortalize cells (Han et al., 2008). In effect, H IF-la 
expression in the normal gland attached to the primary tumor could indicate the portion 
of the gland that may be initiating tumorigenesis.
PyVT mice also have different patterns of radioiodine accumulation correlating
with overall tumor size. The shift from a center to edge pattern at early stages of
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premalignancy to multi-spot suggests that the gamma camera can detect the shift to 
malignancy. Maglione et al. (2001) described the topographical zones of the PyVT gland 
in which the zone closest to the nipple was the first to develop hyperplastic nodules. With 
gamma imaging it may be possible to identify these topographical zones by examining 
the contour plots of tumors in which multi-spot patterns of radioiodine uptake would 
suggests that the hyperplastic lesion had spread from the nipple into the mammary fat 
pad.
Moreover, a PyVT mouse that was imaged three times to monitor tumor 
progression exhibited both an increase in tumor size and radioiodide uptake in the whole 
tumor. However, at the pixel level which would represent clusters of cells there was a 
steady decrease in the radioiodine accumulation associated with tumor progression. It has 
been well established that as tumors develop in the PyVT model there are losses in 
estrogen and progesterone receptor status in the tumor (Lin et al., 2003). Recently, an 
estrogen responsive element that binds ERa was identified in the promoter region of the 
NIS gene (Alotaibi et al., 2006), which suggests that estrogen has a role the expression of 
the NIS gene. Our data suggest that the decrease in radioiodine accumulation per pixel in 
late stage PyVT tumors may be an indication of the loss of the ER which would affect 
NIS protein expression and radioiodine accumulation.
As an alternative to analyzing tumor pattern, size, or radioactivity the results 
implied that rates of radioiodine accumulation could be very informative in the case of 
moderate and large MMTV tumors. The data suggested that MMTV tumors had two fates 
that corresponded with tumor progression. The first trend was that as some tumors grew 
in size they steadily increased the amount of radioiodine they accumulated, in contrast
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some other tumors with the same size range appeared to reach a plateau or lowered level 
of radioactivity. Cohorts from small, moderate, and large tumors that were associated 
with either trend were analyzed to get the average rate of radioiodine accumulation for 
“high” and “low” trend groups that were matched for size. The data implied that, in 
general, moderately large tumors (>100 pixels) that had a rate of accumulation by a factor 
of 2 more than the low group were correlated with the “high” trend group. These data 
suggest that in addition to size, pattern, and radioactivity, rates of radioiodine 
accumulation also can predict tumor type.
Considering the wealth of data that was collected from the 58 mice imaged in this 
study, a principal component analysis was used to reduce the data variables in order to 
observe any data relationships that may have been missed. The PCA analysis extracted 
three major components that accounted for over 60% of the variance in all the data. These 
components involved percent of radioiodine accumulated by the tumor, the pregnancy 
factor, and the body location of the primary tumor site. The principal component analysis 
confirmed our initial observations that tumor size and the percent injected dose 
accumulated were highly correlated. The association of pregnancy with the age of the 
animal demonstrated that tumorigenesis is specifically associated with old nulliparous or 
younger pregnant/previously pregnant mice is consistent with the earlier observations that 
chances of tumor development increases with parity due to hormone response (Cardiff 
and Kenney, 2007; Kordon, 2008). Additionally, the pregnancy component was also 
correlated with the number of tumors a mouse has at the time of imaging. The third 
component indicated that that the location of the mammary tumor was correlated with the 
body weight of the animal was unexpected. Based on the PCA scores, mice that have
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cervical or upper thoracic tumors had a lower body weight than mice with tumors in the 
lower thoracic, inguinal, and abdominal regions. This could be influenced by the fact that 
inguinal tumors are harder to visually detect because these tumors are obscured ventrally 
until late in tumor development. Therefore, this correlation could be strongly influenced 
by current animal husbandry practices that restrict animal handling to cage changes every 
two weeks.
Difference plots have the potential to be very informative by indicating not only 
areas of radioactivity gain and loss within a tumor, but also the primary locations of 
functional NIS expression. The pathway of radioiodine transfer within a tumor likely 
defines the sites where the NIS protein is actively accumulating radioiodine. It is also 
possible that because NIS activity can be blocked with high doses of potassium iodide 
(KI) that saturate the thyroid gland with iodine (Hammond et al., 2007) the net loss of 
activity observed in difference plots could be due to NIS saturation. Once the protein is 
saturated any residual isotope would wash away and appear as a loss in activity. 
Furthermore, an hour imaging session may be long enough to detect radioiodine washout 
from the tumors. Early radioiodine washout also has been linked to poor prognosis of 
lesions because the therapeutic dose does not remain in targeted tissues (Hung et al., 
2009).
Of note was the applicability of the gamma camera to detect radioiodine 
accumulation in putative normal mammary glands of tumor-bearing mice. Under normal 
conditions NIS expression is tightly regulated in order to add iodine to milk, and during 
this time is sensitive to radioiodine uptake (Tazebay et al., 2000). Therefore, these data 
suggest that when a tumor develops there may be a disregulation on gland tissue to
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overexpress NIS. In the MMTV model Wnt, fibroblast growth factor (FGF), and notch 
signaling are activated during tumorigenesis (Theodorou et al., 2007), and genes specific 
to each pathway have been linked to regulating components of NIS expression the 
thyroid (Boelaert et al., 2007; Ferretti et al., 2008; Kim et al., 2007b). This suggests that 
the overexpression of either the Wnt, or FGF pathway in the MMTV model could cause a 
broad effect on other mammary glands. Furthermore, parous MMTV-infected mice form 
neoplastic hyperplastic alveolar nodules (HANs) that along with primary tumors can 
become independent of hormonal regulation (Kordon, 2008). Taken together, these data 
indicate that the gamma camera may detect early tumor states in the MMTV model.
The efficacy of gamma imaging to detect mammary metastasis requires further 
study as well. In the PyVT model the majority of females exhibit lung metastasis by 
three months of age (Guy et al., 1992). Due to the fact these metastasis are of mammary 
origin, metastatic radioiodine accumulation could possibly be detected with the gamma 
camera if the foci were large enough and not obstructed by the tumor proper. Recently, 
reports have indicated that the disruption of the src gene (SRC-1) in PyVT mice suppress 
metastasis but not tumor formation, suggesting that the src pathway which is also 
upregulated in the PyVT model is involved with the final migration of cancer cells to the 
lungs (Wang et al., 2009).
In comparison studies PyVT mice significantly accumulated more radioiodine and 
at a two times higher rate than spontaneous MMTV mice bearing multiple tumors. PyVT 
tumor histology has been reported to be different than that of spontaneous tumors 
induced by MMTV (Cardiff et al., 2000a). Our data suggest that biology behind the 
differences in tumor morphology can be detected in vivo. More comparative studies
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between the two models would greatly resolve how naturally occurring tumors differ 
from tumors genetically engineered.
FUTURE DIRECTIONS 
Using Other Iodinated Ligands for Gamma Imaging
There are many commercially available ligands that can be iodinated and imaged 
with the gamma camera. In preliminary trials we have imaged MMTV mice with 
iodinated 17p-estradiol, VEGF, and EGF. While our data do not show tumor specificity 
for estrogen or VEGF, there are promising results when imaging with EGF. Four hours 
after administration of the radioactive EGF gamma imaging revealed that the MMTV 
tumor had bound ligand (Fig. 4.4). In addition, immunohistochemical data suggest that 
amphiregulin (AREG), an EGF family member, is expressed in MMTV tumors along 
with NIS (Fig. 4.2a-c). AREG has been shown to be overexpressed in breast cancer and 
will bind to the EGF receptor (McBryan et al., 2008). This could be very informative 
with regard to the PyVT transgenic line which has been shown to increasingly 
overexpress the EGF receptor (HER2/neu) with tumor progression (Lin et al., 2003). 
Moreover, targeting the overexpression of HER2/neu in PyVT tumor progression with 
iodinated AREG or EGF would provide further in vivo information of the molecular 
process of breast cancer.
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Microarray, Real-Time PCR and Gene Expression
An important aspect of continued molecular research with regard to in vivo 
imaging is the global expression of genes implicated in both mouse and human breast 
cancer. Custom designed microarray gene chips and real-time PCR arrays with genes 
associated with mouse breast cancer, estrogen receptor signaling, and breast cancer 
prognosis (SABiosciences) are available commercially. Employing these approaches 
would allow the investigation of which genes associated with breast cancer are expressed 
in MMTV and PyVT tumors. With that information a correlation could be made between 
our sodium iodide symporter real-time data in tumors to validate whether the sodium 
iodide symporter/activity could serve as a biomarker for murine breast cancer. These data 
would potentially provide a wealth of data particularly to those genes that are co­
expressed with the sodium iodide symporter, and this would suggest which gene products 
might be iodinated for future in vivo gamma camera imaging.
Detailed earlier, once a putative gene has been identified for in vivo imaging, 
subsequent immunohistochemistry on corresponding proteins could be done on tumor 
tissues to derive the molecular pattern related by the gamma image. Assessment of the 
protein localization coincident with the sodium iodide symporter gamma camera position 
and pattern would provide great value to application of the camera in producing an in 
vivo molecular “signature” of tumorigenesis.
Computer Pattern Recognition Programs for In Vivo Studies
The in vivo study on MMTV mammary tumors has implicated that l2?I 
incorporation patterns correlate with overall tumor size. These patterns have the potential
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to provide powerful information about the biology of the tumor at the time in which it 
was imaged. Unfortunately, a drawback to this process was that all uptake patterns were 
assigned manually. In an effort to reduce any type of bias in pattern assignment computer 
based programs could be designed to select the 12H uptake pattern immediately after 
imaging.
In mammography and ultrasound automated segmentation of region of interest 
(ROI) identifies tumor mass morphology by factoring in edge gradient and pixel intensity 
in a contour plot (Cui et al., 2009; Song et al., 2009). In addition, tumor volume 
predictors using segmentation have been used in PET (Drever et al., 2007). In PET and 
SPECT the volume of interest (VOI) predicts and quantifies tumor size and radionuclide 
uptake based on designed algorithms (Blackwood et al., 2009; Wahl et al., 2009).
Current computer based pattern recognition programs regardless of imaging 
modality require calculated standards to assess tumor morphology patterns. Incorporating
1 ^  C
some form of computer based pattern recognition of I uptake would only increase the 
validity of in vivo gamma imaging.
CONCLUSION
12sHere we describe the in vivo efficacy of a novel gamma camera to image U 
metabolism in mammary tumors of the MMTV and PyVT mouse models. Our data 
suggest that 12 'I accumulation, as detected by the gamma camera, is highly correlated to 
areas within tumors where the sodium iodide symporter is expressed. In addition, the 
gamma camera can be readily applied to genetically engineered mouse models, which 
share similar tumorigenesis pathways and histology with human breast cancer. Our
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results also indicate that the classifiable heterogeneity present in dynamic gamma camera 
images may correlate with specific patterns or signatures of gene expression that, in turn, 
indicate tumor subtype and progression. These data may allow investigators to develop 
an effective and sensitive system of in vivo imaging of molecules and metabolism that 
reflect the molecular signature of a tumor in real time. Our system may provide a means 
for early detection, ideally even a precancerous state before malignancy develops, and a 
method to assess the overall state of a tumor with the goal of predicting the best 
therapeutic regime and following the efficacy of the therapy in real time by examining 
specific molecular targets.
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Figure 4.1. (a) Low power (lOx) H&E stain o f a cryosectioned multi-spot tumor showing necrotic pools 
(red stain) within the tumor tissue, (b) Low power (lOx) apoptosis and necrosis stain on a cryosectioned 
multi-spot tumor showing discrete areas necrotic (red) and apoptotic (green) cells, (c) High power (40x) 
view o f the apoptotic (green) and necrotic (necrotic) cells o f a multi-spot tumor.
Figure 4.2. (see next page) (a) Low power (20x) immunohistochemical staining for AREG in a multi-spot 
tumor, (b) Low power (20x) localization o f NIS protein in the same field o f view as (a), (c) Overlay image 
of (a) and (b) showing the discrete expression patterns o f AREG and NIS. (d) Low power (20x) localization 
o f H IF -la  protein in a different multi-spot tumor, (e) Low power (20x) immunolocalization o f NIS protein 
in the same field o f view as (d). (f) Overlay image o f (d) and (e) showing the discrete expression patterns of 
H IF -la  and NIS.
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Figure 4.3. (a) Gamma camera detects five tumors in an MMTV animal, (b) Bright field image o f the left 
inguinal tumor (a, Tum3). (c) Immunolocalization for the H IF -la  protein appears to be primarily expressed 
in the normal portion o f the mammary gland next to the tumor, (d) Overlay image o f (b) and (c) further 
shows that the putative normal gland next to the tumor is where H IF -la  is expressed, (e) 2x bright field 
image o f the mammary gland next to the primary tumor, (f) 2x localization o f H IF -la  protein in the 
mammary gland, (g) Overlay image o f (e) and (f) showing the discrete expression pattern o f H IF -la  in the 
mammary gland next to the primary tumor. (Sal = salivary glands, Thy = thyroid, Turn = tumor, Sto -  
stomach, Inj = injection site)
Figure 4.4. Gamma camera imaging o f an MMTV 
animal 4 hours after the administration o f iodinated 
EGF. The signal appears to be specific to the mammary 
tumor. (Thy = thyroid, Turn = tumor, Bla = bladder, Sto 
= stomach, Inj = injection site)
Turn
Thy
Sto
Bla •
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APPENDIX
IN  VIVO IMAGING OF THE SODIUM IODIDE SYMPORTER ACTIVITY IN 
THE MOUSE THYROID USING MULTI-PINHOLE HELICAL SPECT 
ABSTRACT
In vivo functional imaging of molecular processes in discrete organs is 
particularly challenging with small animals because non-damaging radiotracer dosage 
limitations can compromise image resolution and sensitivity. Imaging modalities 
designed to address this issue while maintaining high image quality have become a 
primary goal of molecular imaging research. An economical multi-pinhole helical 
SPECT (mphSPECT) system suitable for imaging the mouse thyroid with radioiodine
1 9 S( T) was developed requiring both high resolution and low radioactivity for in vivo 
imaging. The characteristic bilobal structure of the thyroid was resolved with minimal 
radioiodine dosage (7.4 MBq / 200 pCi). Also the expression of the sodium iodide 
symporter (NIS) was examined in the thyroid gland and validated the efficacy of 
mphSPECT for molecular targeting. The data suggest potential molecular imaging 
applications of mphSPECT for a variety of studies on NIS-expressing tissues in mice, 
such as thyroid, gastrointestinal tract or mammary tumors.
INTRODUCTION 
The Sodium Iodide Symporter
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The sodium iodide symporter (NIS) is a plasma membrane glycoprotein 
containing 13 transmembrane domains with extracellular (amino) and intracellular 
(carboxyl) termini (Levy et al., 1998; Smanik et al., 1997). NIS is responsible for the 
active transport of an iodide ion against its concentration gradient to be cotransported 
with two sodium ions generated by the gradient of the sodium/potassium ATPase. Iodide 
is transported by NIS from the blood into thyroid follicular cells, where it is organified 
for thyroid hormone synthesis. NIS specific expression in the thyroid gland is regulated 
by the thyroid stimulating hormone (TSH) secreted by the pituitary gland (Carrasco,
1993).
Other organs that endogenously express NIS and have the capacity to accumulate 
iodide include the salivary gland, nasolacrimal duct, placenta, gastric mucosa and the 
lactating mammary gland (Dai et al., 1996; Tazebay et al., 2000). NIS expression in the 
gastric and salivary gland suggests an avenue for iodide secretion into the gastrointestinal 
tract for reabsorption into the bloodstream for thyroid use (Josefsson et al., 2002). 
Mammary gland NIS expression occurs in response to circulating pregnancy hormones 
and used to supply iodide from the bloodstream to the milk substrate for neonatal thyroid 
development (Tazebay et al., 2000). Between species cloned NIS of the mouse was found 
to have 95% homology with that of rat and 81% homology with the human form (Perron 
et al., 2001).
The Thyroid Gland
The thyroid gland is an endocrine organ located in the cervical region and is 
responsible for the production of hormones that influence cellular metabolism and 
maintenance of the basal metabolic rate (Larsen et al., 1998). As needed, thyroid
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releasing hormone (TRH) is released from the hypothalamus, stimulating the 
adenohypophysis of the pituitary gland to secrete thyroid stimulating hormone (TSH) into 
the bloodstream. TSH acts on thyroid acini or follicular cells to stimulate organification 
of iodine and secretion of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4) 
into the bloodstream in order to modulate mitochondrial efficiency. Thyroid hormone 
precursors are stored in the colloidal region of each thyroid follicle in order to respond 
rapidly upon physiologic need or dietary depletion of iodine (Larsen et al., 1998).
The thyroid also contains parafollicular, or C, cells that secrete calcitonin 
hormone responsible for lowering blood calcium levels. Calcitonin specifically inhibits 
bone resorption by binding to osteoclasts, but may have a role in the central nervous 
system, testes, and skeletal muscle (reviewed in Elisei (2008)). C cells are oriented either 
individually or in clusters between thyroid follicles, and are derived from a different 
embryonic origin than follicular cells (Larsen et al., 1998).
The Mouse Thyroid Gland
Active biosynthesis and secretion of thyroid hormones are predominant in the 
mouse model. The embryonic mouse thyroid gland initiates iodine accumulation and 
hormone biosynthesis after 15 days post coitum (dpc) (Fagman et al., 2006; Postiglione et 
al., 2002), but function is subject to NIS expression (Szinnai et al., 2007). In addition, 
maximum levels of TSH and thyroid hormones correlate with the maximum iodine 
uptake between 30-60 days in different mouse lines which decrease with age (Sawitzke et 
al., 1988). Evidence also suggests a disparity in thyroid function between the sexes 
whereby females have greater 13!I uptake, which varies based on the estrus cycle (Chai, 
1970). Environmental factors, metabolic rates and circadian rhythms are also linked to
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mouse thyroid hyperactivity which ultimately correlates with decreased lifespans 
(Buffenstein and Pinto, 2009).
At the molecular level mice have increased thyroid activity compared to humans 
as well. Recently, differences between human and mouse NIS efficiency of iodide 
transport have been documented in transfected human embryonic kidney 293 cells. 
Immunolocalization comparisons between human and mouse NIS found that the mouse 
counterpart localized predominately to the cell membrane, while approximately two- 
fifths of cells transfected with human NIS had intracellular protein localization (Dayem et 
al., 2008). The majority of thyroid follicles in the mouse express NIS (Josefsson et al., 
2002), by contrast at any particular time approximately one-fifth of human thyroid 
follicles express NIS (Faggiano et al., 2007). We have reported that the potassium iodide 
dosage required for the Wolf-Chaikoff blocking effect is higher in mice than the dose 
recommended for humans (Hammond et al., 2007).
Imaging the Discrete Lobes of the Mouse Thyroid
In vivo imaging strives to develop tools that follow molecular and physiological 
processes repeatedly and non-invasively over the lifetime of the organism. The two 
discrete lobes of the mouse thyroid are particularly challenging for in vivo imaging 
because of its small size and narrow (1-2 mm) lobe separation. Two studies (Hong et al., 
2006; McElroy et al., 2002) have shown the capability of single-pinhole SPECT to 
resolve the bilobal structure of the mouse or rat thyroid using higher 12>I doses to the 
order of 37 MBq (1 mCi). There are reports of the successful resolution of the bilobal 
structure of the mouse thyroid using planar imaging with small pinholes (100-250 pm)
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(Beekman et al., 2002) or coded apertures (Accorsi et al., 2008), which are accomplished
125with I doses of about 10 MBq (270 pCi) to fit the pinhole or aperture dimension. 
Radioactive Dose Considerations for Imaging
It is vital that small animal imaging experiments are designed to employ the 
lowest possible dose of radioactive material whenever medium or long-term in vivo 
studies are undertaken. While the long half-life (59.4 days) of 125I is very useful for 
metabolic studies, it also raises concerns about excessive radiation exposure that could 
damage tissues sensitive to radioiodine such as the thyroid. Therefore, employing high 
radioactivity doses must be carefully considered (Hammond et al., 2007). Several studies 
have indicated growing concern over high-radiation doses employed in small animal 
studies (Acton, 2006; Difilippo, 2008; Funk et al., 2004; Kung and Kung, 2005; Liang et 
al., 2007; Peremans et al., 2005). Reducing the amount of radioactivity used in 
experiments makes in vivo, high-quality molecular imaging of small organs such as the 
mouse thyroid a challenge.
Multi-pinhole Single Photon Emission Computed Tomography (SPECT)
Multi-pinholed SPECT can be employed to address issues of image quality with 
reduced radioactivity, while also taking advantage of a large number of readily available 
ligands tagged with radionuclides such as 125I and " mTc (Beekman and van der Have, 
2007; Beekman et al., 2005; Goertzen et al., 2005; Hesterman et al., 2007; Jansen and 
Vanderheyden, 2007; Kim et al., 2006; Meikle et al., 2002; Schramm et al., 2003; 
Vanhove et al., 2008). Both phantom and animal studies have demonstrated the value of 
multi-pinhole SPECT for small animal imaging (Forrer et al., 2006; Gotthardt et al.,
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2006; Liu et al., 2008; Nuyts et al., 2009; Ostendorf et al., 2006; Pissarek et al., 2008; van 
der Have et al., 2008).
Hypothesis and Predictions
We have recently designed an economical multi-pinhole helical SPECT system 
for small animal imaging that is appropriate for a typical biology research laboratory 
(Qian et al., 2008). Our data, based on phantom studies, suggested multi-pinhole helical 
SPECT could be utilized to image small animal tissues with high-resolution and good 
sensitivity. As an in vivo proof-of-concept demonstration, multi-pinhole helical SPECT 
was used to image the living mouse thyroid gland while maintaining a relatively low-
1 9 Slevel dose of I (7.4 MBq / 200 pCi). Herein, we aim to demonstrate the efficacy of our 
system for molecular targeting by examining the expression of NIS in the mouse thyroid 
gland. If multi-pinhole helical SPECT is capable of imaging and resolving the discrete
19^  •lobes of the thyroid with I, then we predict that the thyroid image produced will 
correlate with the expression of NIS protein, which facilitates iodine transport into 
thyroid cells.
MATERIALS AND METHODS 
Multi-pinhole Helical SPECT Imaging System
Design and functional details of this system have been presented in an earlier 
report which employed only phantoms (Qian et al., 2008). Briefly, a 110 mm diameter 
circular detector based on a Hamamatsu R3292 position-sensitive photomultiplier tube
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(PSPMT) mounted on a cylindrical gantry capable of 360° rotation was employed for 
gamma-ray imaging. The R3292 module was air-coupled to pixellated Nal(Tl) 
scintillators measuring 1><1 ><5 mm3 separated by 0.2 mm reflective septa. A step-and- 
shoot helical orbit was effected by incorporating two computer-controlled stepping 
motors driving the rotation of the gantry around the axis of rotation (AOR) and the 
translation of the animal bed along the AOR. Each scan obtained projections at 120 
angular positions with 3° intervals. A 5 mm thick, multi-pinhole brass collimator suitable 
for 125I imaging was designed so that each pinhole is 1 mm in diameter with a 0.2 mm
channel height and an opening angle of 90°. In the present work, two pinholes were
employed by covering unused pinholes with 0.5 mm thick lead foil to block photons 
125emitted from I. The radius of rotation was 25 mm from the collimator with a 
magnifying factor of 3 (focal length: 75 mm) used in the studies. This setup resulted in a 
field of view with a diameter of -  51 mm. Previous measurements showed that a full- 
width at half maximum (FWHM) resolution of -  1.3 mm was achieved using two-pinhole 
helical SPECT with a sensitivity of 80.6 cps/MBq (Qian et al., 2008).
SPECT projection data in this study were acquired over 360°. Parameters for 
SPECT scans are variable and thus are stated for each specific case. The image 
reconstruction approaches were based on the iterative maximum likelihood-expectation 
maximization (ML-EM) algorithm extended from the method described by Li et al (Li et 
al., 1995) with Siddon’s ray tracing technique implemented (Siddon, 1985). The 
reconstructed images were smoothed with a Hann filter. No attenuation correction was 
applied in this work. The reconstruction used 0.4-mm cubic voxels. Data collection from
imaging was provided by collaborator Dr. Jianguo Qian.
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Mouse Model
Two mice from the C57BL/6J strain (Jackson Laboratory, Bar Harbor, Maine)
were selected to demonstrate the in vivo efficacy of the two-pinhole helical SPECT
125system. The first mouse was injected with 4.8 MBq (130 pCi) Na I, and imaged 24 
hours after the dose was administered. The mouse expired during the third hour of 
imaging due to an adverse reaction to anesthesia, but imaging continued for four hours. 
The thyroid was resected at the end of the imaging period, and a direct measurement of 
the accumulated dose was taken with a Ludlum survey meter fitted with a scintillation 
probe.
The second mouse was imaged 24 hours after receiving a 7.4 MBq (200 pCi) dose
125of Na I for two hours. The mouse was returned to its cage after imaging fully
recovered. This study was performed in accordance with protocols approved by the 
College of William & Mary IACUC animal committee. Anesthesia of animals was 
performed using sodium pentobarbital (50-90 mg kg'1 body mass) injected into the 
peritoneal cavity.
Whole-mount Immunohistochemistry
Whole mount immunohistochemistry was modified from (Johnstone et al., 2000) 
and used to localize the NIS protein in the thyroid. The thyroid from the first mouse was 
excised along with the trachea and esophagus to preserve the natural anatomical bilobal 
structure. The tissue was fixed in 4% paraformaldehyde for 24 hours at 4 °C. After 
fixation the tissue was briefly rinsed with phosphate buffered saline (PBS) and 
permeabilized with PBT (PBS + Triton X-100). Non-specific binding was blocked with
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2% bovine serum albumin (BSA) in PBT for 6 hours. The whole thyroid was incubated 
with rabbit anti-rat NIS primary antibody (Alpha Diagnostic Int., San Antonio, Texas) for 
60 hours at 4 °C, and then rinsed with 2% BSA in PBT. Finally, the thyroid tissue was 
incubated overnight at 4 °C with fluorescent-labeled goat anti-rabbit Alexa-488 
secondary antibody (Invitrogen, Eugene, Oregon), and then rinsed in PBT. Bright field 
and fluorescent photographs (using a fluorescein filter) were taken with an Olympus 
MagnaFire DP71 camera and an overlay image was created using Adobe Photoshop 7.0.
Sectioning and Histology
Following whole-mount immunohistochemistry preparation the light sensitive 
thyroid was infiltrated with 1.6 M sucrose/PBS and incubated at 4°C overnight. The 
thyroid was then infiltrated with 50/50 solution of sucrose and O.C.T. freezing media 
(Triangle Biomedical Sciences Inc, Durham, NC) for four hours followed by two-hour 
incubation in O.C.T. media. The gland was transferred to a boat with fresh freezing 
media and placed on the freeze plate of the Minotome Plus (Triangle Biomedical 
Sciences Inc, Durham, NC) cryostat machine at -40°C until the freezing media solidified. 
The frozen tissue block was removed from the boat and mounted to a pin with excess 
freezing media. The frozen tissue was sectioned inside the Cryostat chamber at -22°C at 
a thickness of 10 pm.
Tissue slides were rinsed in PBS for five minutes, mounted with nuclear stain 
Vectorshield with DAPI (Vector Laboratories, Burlingame, CA), and stored at 4°C. 
Sections were photographed with an Olympus 1X50 inverted fluorescent microscope 
equipped with an Evolution MP digital camera using fluorescein (488 nm). UV filtered
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light was used also for DAPI visualization. Composite figures of fluorescent and DAPI 
images were created using Adobe Photoshop CS3 Extended Version 10.
A subset of thyroid sections were counterstained with hematoxylin and eosin, then 
subsequently dehydrated in graded alcohol series, cleared and mounted to assess thyroid 
histology.
RT-PCR
Total RNA was isolated from frozen tissues by RNeasy Midi and Maxi kits 
(QIAGEN, Valencia, CA). Ambion (Foster City, CA) DNA-free DNase I treatment was 
applied to the total RNA prior to cDNA synthesis. One microgram of total RNA was 
reverse transcribed using a Biorad iScript cDNA synthesis kit (Hercules, CA). Intron- 
spanning PCR primers for NIS were designed using PrimerS software 
(http://frodo.wi.mit.edu/) and confirmed to be highly specific for mouse NIS using 
nucleotide BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). The primer sequences for 
NIS were the following:
sense 5’ GCTCTCATTCATCTATGGCTCAAC 3’; 
anti-sense, 5’ GGTGAAAGCGCCAAGGAGAG 3’.
Beta-actin primers (Perron et al., 2001) were used in a parallel reaction for an internal 
control. PCR was carried out using taq polymerase (New England Biolabs, Beverly, 
MA) following the manufacturer's protocol with the cycle parameters: 94°C hot start for 
5 min, 40 cycles of denaturation at 94°C for 30 sec, annealing at 64°C for 1 min, and 
extension at 72°C for 2 min, followed by an extension at 72°C for 7 min. Liver was used 
as a negative tissue control for NIS mRNA expression. As a negative control for each 
PCR reaction, reverse transcriptase was replaced with H20  in the cDNA synthesis
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reaction. PCR products were separated on a 1.2% agarose gel and stained with ethidium 
bromide. Gels were visualized under UV light with a Biorad gel documentation system 
using Quantity One Software. Data for rt-PCR was provided by collaborator Stephen 
Schworer.
Data Analysis and Statistics
Images of the mouse thyroid from immunohistochemistry and mphSPECT 
imaging were converted to 32-bit grayscale and pixel intensity and luminescence was 
quantified using ImageJ 1.40g. The thyroid immunohistochemical image was resized to 
the scale of the mphSPECT image for analysis. Statistical analysis consisted of Student’s 
t-test and was performed using Statistical Package for the Social Sciences (SPSS) 
software. Pixel intensity was compared between the left and right lobes of the thyroid.
RESULTS
Animal studies using in vivo multi-pinhole helical SPECT can resolve the two lobes 
of the mouse thyroid
Anatomically, the approximate separation between the two lobes of the 
C57BL/6J-derived mouse thyroid was between 1.8-2.5 mm, depending upon the position
125along the margin of the thyroid. Using an overall injection of 4.8 MBq (130 pCi) Na I 
this relationship was demonstrated after 24 hours during the first imaging session with a 
1.2 mm thick coronal image slice reconstructed from the 4-hour multi-pinhole helical 
SPECT scan (Fig. la). Direct measurement of the resected thyroid with a scintillation 
probe survey meter indicated that the radioactivity absorbed by the thyroid was about
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0.37 MBq (10 |uCi). From this measurement the final percent of the injected dose 
remaining in the thyroid gland was 7.7 %.
The second mouse was injected with 7.4 MBq (200 pCi) Na12?I and imaged in 
vivo after 24 hours as well. The subtle bilobal structure of the thyroid was delineated with 
a 1-min multi-pinhole projection of the thyroid region. Fully covering the whole thyroid 
region of the mouse, the 4.8 mm thick coronal image from the same multi-pinhole helical 
SPECT scan correctly indicated the shape and separation of the lobes (Fig. lb). Using 
region of interest (ROI) covering the thyroid indirectly measured the radioactivity to be 
approximately 0.7 MBq (18.9 pCi), which accounted for approximately 9.5% of the 
injected dose. The in vivo animal studies demonstrate that two-pinhole helical SPECT 
successfully resolved the fine structure of the mouse thyroid within two hours (summary 
in Table 4.1).
Multi-pinhole helical SPECT can detect the functional activity of the sodium iodide 
symporter
In order to validate whether mphSPECT imaging correlates with the molecular 
activity of the sodium iodide symporter ion channel, the macro protein expression of NIS 
was assessed in the thyroid of the first mouse via immunohistochemistry (Fig. lc-e). NIS 
localization was indirectly detected with a fluorescent secondary antibody in the two 
lobular regions of the thyroid (Fig. Id). The lobular regions of the thyroid were 
subsequently cryosectioned to further substantiate that whole-mount NIS localization was 
specific at the cellular level in the thyroid follicles (Fig. lf-h). NIS was indeed shown to
be expressed in the thyroid follicular cells which are the site of iodide uptake for 
hormone biosynthesis (Fig. le). As expected, total RNA extracted from C57BL/6J 
thyroid tissue showed the expression of NIS mRNA for translation into functional protein 
(Fig. li).
Semi-quantitative measures of pixel intensity were analyzed for both the 
mphSPECT and the whole-mount immunohistochemical images for the first mouse. The 
images were converted to gray scale and the immunohistochemical image was scaled 
down to the size of the mphSPECT image. Based on ROI data of the whole thyroid both 
images followed the same trend of increased pixel intensity in the lobular regions (Fig. 
2a). The three-dimensional pixel luminescence of both image types further delineated 
increased pixel intensity in the two lobes. Although the mphSPECT three-dimensional 
image appears uniform in luminescence intensity, the immunohistochemical three- 
dimensional image represents a more accurate luminescence scale because the peaks 
within the lobular regions become fused in the mphSPECT image (Fig. 2b). In order to 
assess whether there was a significant difference in pixel intensities between the left and 
right lobes of the thyroid, ROIs (8 x 40 pixels) were placed on each lobe of both image 
sources. The data suggest that both mphSPECT (p<0.05) and immunohistochemistry 
(p<0.01) images had significantly more pixel intensity in the left lobe of the thyroid 
compared to the right (Fig. 3). These results strongly demonstrate that multi-pinhole 
helical SPECT specifically detects the functional activity of NIS protein responsible for 
125I uptake in the living mouse thyroid gland.
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DISCUSSION
Molecular imaging studies employing SPECT with small animals encounter 
trade-offs between high spatial resolution with the use of high doses of radio-labeled 
ligands and limiting the duration of exposure to radioactive materials which may damage 
tissue and compromise the health of the experimental subject (Funk et ah, 2004; Kung 
and Kung, 2005; Peremans et ah, 2005). For example, longitudinal in vivo studies 
suggest excessive iodine accumulation and retention can have significant pathological 
implications (Hammond et ah, 2007) (Ronckers et ah, 2006). However, this study 
demonstrates the application of our economical multi-pinhole helical SPECT that is 
effective for low-dose, high-quality in vivo molecular imaging. We found that 24 hours 
after administering a low dose of Na125I (7.4 MBq / 200 pCi) our detector was capable of 
reconstructing the discrete anatomical structure of the two lobes of the mouse thyroid 
which are separated by only 1-2 mm. Finally, ex vivo expression analysis of the sodium 
iodide symporter was shown to localize in the resected thyroid lobes in the same 
locations as the pattern of radioiodine distribution in the multi-pinhole helical SPECT 
images. Therefore, it appears that multi-pinhole helical SPECT effectively images the 
activity and location of the sodium iodide symporter, the target of radioiodine imaging in 
the thyroid gland.
Using two pinholes and a relatively high magnifying factor of three, the
projections for the entire bilobal thyroid gland can be completely detected from either
pinhole and at each detector position during the entire helical SPECT scan, even as the
position of the mouse changes along the axis of rotation. For our study, additional
pinholes did not significantly improve sensitivity or image quality since truncation
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occurred when three or more pinholes were employed, though others have reported on the 
success of imaging with more than two pinholes (Ostendorf et al., 2006) (Funk et al., 2006). 
We anticipate that the design of a new multi-pinhole collimator with a more compact 
pinhole pattern coupled with an appropriate magnification factor will allow us to apply a 
greater number of pinholes in the system and thereby facilitate shorter scan time and an 
even lower injection dose.
Other examples of multi-pinhole helical SPECT systems have been developed 
(Difilippo, 2008; Lackas et al., 2004) and two commercial small animal imaging systems, 
the NanoSPECT (Koninklijke Philips Electronics 2009) and U-SPECT-II (MILabs 2008),
1 9 Shave multi-pinhole and helical SPECT capability. A prior in vivo T SPECT study was 
reported by McElroy et al (McElroy et al., 2002) using single-pinhole SPECT and an
125
injected dose of 37 MBq (1 mCi) T with a 16 min. imaging period. Compared to that 
study, our in vivo two-pinhole helical SPECT study has a lower dose and longer imaging 
time (2 hours). The longer imaging time in our study results from an approximately 1.8 
reduction in sensitivity of our two-pinhole gamma camera compared with the LumaGEM 
detector used in the McElroy et al study (McElroy et al., 2002). Additionally, the 
McElroy team imaged the mouse 7.5 hours post injection, while we imaged a full 24 
hours post injection. Longer times between injection and imaging are important for 
metabolic and functional studies of the thyroid (Meikle et al., 2005); though Ferreira et al 
(Ferreira et al., 2005) have suggested radioiodine content measured after 15 min. of 
administration can efficiently evaluate basolateral iodide transport. Taken together, our 
two-pinhole helical SPECT system achieved excellent image quality along with 
significant dose reduction.
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Multi-pinhole helical SPECT has numerous biomedical applications with the 
thyroid. NIS expression is the driving force behind radioiodide treatment for thyroid 
cancer with targeted radioiodide uptake destruction of metastatic cells after 
thyroidectomy (Carrasco, 1993). Radioiodine imaging targeting NIS can be utilized for 
imaging the metabolic differences between hyper- and hypothyroidism (Chung, 2002; 
Dadachova and Carrasco, 2004). Likewise, our imaging system would be beneficial for 
imaging genetically engineered mouse models in order to characterize thyroid cancer 
(reviewed in Knostman et al. (2007a)). As NIS is generally under expressed in thyroid 
cancer, different methods for increasing its expression for radioiodine therapy could be 
evaluated using our system, along with imaging metastatic tumors post-treatment (Aide et 
al., 2009; Schipper et al., 2007; Spanu et al., 2009). The work presented here suggests the 
potential of employing multi-pinhole helical SPECT with other tissues expressing the 
sodium iodide symporter such as gastric and breast cancer studies (Dadachova and 
Carrasco, 2004; Dohan and Carrasco, 2003; Perron et al., 2001).
Table 1. Summary of imaging information for mice analyzed with mphSPECT.
Mouse Na123I Dose Image Lapse Image Duration %ID in Thyroid
1 130 pCi 24 hours 4 hours 7.7 % ID
2 200 pCi 24 hours 2 hours 9.5 % ID
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Figure 1. (a) A reconstructed coronal image from the 4 hour multi-pinhole projection image with the 
central pinhole near the thyroid region o f the first mouse, (b) A reconstructed coronal image from the 2 
hour multi-pinhole projection image with the central pinhole near the thyroid region of the second mouse.
(c) Anatomy of the resected first mouse thyroid showing the lobes flanking the trachea, (d) Whole-mount 
immunolocalization of NIS protein (green signal) with anti-NIS primary antibody, (e) Overlay o f (c) and
(d) localizing NIS protein in the lobes o f the thyroid, (f) Mouse thyroid histology (40x) identifying the 
circular follicles where NIS is expressed, (g) High power (40x) localization o f NIS in mouse thyroid 
follicles from whole-mount tissue sections (c). (h) Overlay o f (g) with DAPI counterstaining o f follicular 
cell nuclei, (i) Total RNA extracted from mouse thyroid expresses NIS mRNA for functional protein 
translation, (th = thyroid, tr = trachea)
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Figure 2. (a) Plot profiles of mphSPECT (dotted line) and NIS localization (solid line) images of the 
thyroid exhibit similar trends of pixel intensities (inset gray scale mphSPECT (top), NIS localization 
(bottom), (b) Gray scale three dimensional pixel luminescence profiles of mphSPECT (left) and NIS 
localization (right) images further indicate that the imaging modality and NIS activity are coincident in the 
mouse thyroid (inset luminescence scale). (RL = right lobe, LL = left lobe)
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Plot Profile ROIs of ttie Gray Scale Pixel Intensity of Na125l Accumulation Using mphSPECT 
and the Indirect Localization of NIS in the Mouse Thyroid Lobes
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Figure 3. ROI analysis o f the individual mouse thyroid lobes suggests a significant difference in gray scale 
pixel intensity between the two lobes in both N al25I uptake and NIS protein localization. ROIs (8 x 40 
pixels) placed on each individual lobe o f the thyroid whether using mphSPECT (p < 0.05) or NIS protein 
localization (p < 0 .01) are significantly different in the gray scale pixel intensity. The data indicate that the 
left lobe of the C57 mouse accumulated more N al25I which can be attributed to increase in the amount of 
functional NIS protein.
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DUAL MODALITY APPLICATION OF THE GAMMA CAMERA
Earlier our team developed a versatile apparatus capable of dual modality planar 
imaging with a first-generation gamma camera (described in (Weisenberger et al., 1998)) 
coupled with a Lixi fluoroscopic X-ray (Saha et al., 2003). This device was capable of 
monitoring radioiodine uptake in sensitive tissues, as well as providing anatomical 
information. We are currently working to expand dual modality imaging to include other 
modalities that can target molecular markers and events in tumorigenesis.
Currently, angiogenesis detection has become an area of active research for in 
vivo imaging application (Ahmadi et al., 2008; Almutairi et al., 2009; Lijowski et al., 
2009). The premise being that for a tumor to proliferate and eventually metastasize there 
must be adequate blood supply. In particular, avp3 integrins have been shown to be 
involved with angiogenesis in both normal and tumor tissue, and these behave as 
receptors for different ligands expressing arginine-glycine-aspartic acid (RGD) 
(Schottelius et al., 2009). Many have studied in vivo dual modality imaging of 
angiogenesis in relation to vascular endothelial growth factor receptor (VEGFR) using 
PET, SPECT, and optical imaging (reviewed in Cai and Chen (2008)).
In our preliminary in vivo study an economical SBIG-ST6 cooled CCD camera 
(Santa Barbara Instrument Group) has been used to image RGD-linked quantum dots (Q- 
dots) (Invitrogen, Eugene, OR) that target angiogenesis. These Q-dots emit photons at an 
800 nm wavelength that can be detected when excited by blue light-emitting diodes 
(LEDs). In our preliminary work, Q-dot detection was combined with gamma camera
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functional imaging of the sodium iodide symporter in MMTV tumor bearing mice (Fig.
4).
These initial results have suggested that in the MMTV model very little 
angiogenesis has taken place in a developed tumor compared to the inguinal mammary 
glands that did not show evidence of primary tumor. In comparison, the sodium iodide 
symporter activity was most pronounced in the primary tumor, but was also detected at 
lower levels in the non-involved mammary glands (Fig. 5). While the results appeared to 
be promising, more experimental work and analysis must be completed.
The natural beginning point would be to target VEGFR expression with the 
gamma camera while comparing the radioisotope uptake with Q-dot signal in order to 
validate whether both signals are coincident. For example, Fig. 5 (I-M) displays the
1 9 Sunique distribution patterns of I (Fig. 51), RGD-Q-dot (av(33 integrins, Fig. 5J), and 
sodium iodide symporter protein (fluorescent antibody signal, Fig. 5K) in the putative
125normal mammary gland of a MMTV tumor bearing mouse. As expected, the I signal 
and protein expression correlate almost perfectly (Fig. 5M), but the RGD-Q-dot signal is 
not (Fig. 5L). These data validate that 123I and RGD-Q-dots are sensitive molecular 
tracers that can be resolved with our imaging modalities. Therefore, it would be valuable 
to image the VEGFR coupled with RGD-Q-dots to observe whether the two angiogenesis 
markers have similar molecular targeting specificity.
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Q-Dot Optical Image Overlay Q-Dot with GammaGamma Image
Figure 4. In vivo dual modality imaging o f an MMTV mouse with a left thoracic primary tumor. Q-dot 
imaging (left panel) 12 hours after administration showed strong uptake in the right inguinal gland 
compared to the tumor area. Gamma camera imaging (center panel) showed 125I accumulation not only in 
the primary tumor, but also in both inguinal glands. An overlay image o f both modalities (right panel).
Figure 5. Ex vivo dual modality imaging analysis o f a left thoracic and left inguinal mammary gland. (A 
and H) Whole mount image in bright field. (B and I) 5 minute gamma image. (C and J) 60 second Q-dot 
optical image. (D and K) Whole mount immunohistochemistry against NIS where the green signal 
represents NIS protein. (E and L) Composite o f the gamma image with the Q-dot image. (F and M) 
Composite o f the gamma image with NIS immunolocalization. (G and N) Composite o f the bright field and 
NIS immunolocalization.
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